XML 14 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2015	Feb. 12, 2016	Jun. 30, 2015
Document Information [Line Items]
Entity Registrant Name	ANI PHARMACEUTICALS INC
Entity Central Index Key	0001023024
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	ANIP
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2015
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 526.8
Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		11,449,364
Class C Special Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		10,864

XML 15 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 154,684	$ 169,037
Accounts receivable, net of $13,586 and $8,708 of adjustments for chargebacks and other allowances at December 31, 2015 and 2014, respectively	21,932	17,297
Inventories, net	13,387	7,518
Prepaid income taxes	1,127	0
Prepaid expenses and other current assets	1,453	1,139
Total Current Assets	192,583	194,991
Property and equipment, net	7,131	5,223
Deferred tax asset, net of valuation allowance	17,316	15,439
Intangible assets, net	66,397	42,067
Goodwill	1,838	1,838
Total Assets	285,265	259,558
Current Liabilities
Accounts payable	2,066	2,654
Accrued expenses and other	617	567
Accrued royalties	606	702
Accrued compensation and related expenses	1,188	1,348
Current income taxes payable	0	4,253
Accrued Medicaid rebates	4,631	2,264
Returned goods reserve	2,648	1,445
Total Current Liabilities	11,756	13,233
Long-term Liabilities
Convertible notes, net of discount and deferred financing costs	113,427	106,540
Total Liabilities	$ 125,183	$ 119,773
Commitments and Contingencies (Note 12)
Stockholders' Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 11,498,228 shares issued and oustanding at December 31, 2015; 11,387,860 shares issued and outstanding at December 31, 2014	$ 1	$ 1
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December 31, 2015 and 2014, respectively	0	0
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December 31, 2015 and 2014, respectively	0	0
Additional paid-in capital	164,431	159,509
Accumulated deficit	(4,350)	(19,725)
Total Stockholders' Equity	160,082	139,785
Total Liabilities and Stockholders' Equity	$ 285,265	$ 259,558

XML 16 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets [Parenthetical] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Adjustments for chargebacks and other allowances	$ 13,586	$ 8,708
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	1,666,667	1,666,667
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock
Common Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Authorized Shares	33,333,334	33,333,334
Common Stock, Issued Shares	11,498,228	11,387,860
Common Stock, Outstanding Shares	11,498,228	11,387,860
Class C special stock
Common Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Authorized Shares	781,281	781,281
Common Stock, Issued Shares	10,864	10,864
Common Stock, Outstanding Shares	10,864	10,864

XML 17 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Earnings - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Revenues	$ 76,322	$ 55,970	$ 30,082
Operating Expenses
Cost of sales (excluding depreciation and amortization)	12,692	11,473	9,974
Research and development	2,874	2,678	1,712
Selling, general and administrative	21,156	17,935	16,388
Depreciation and amortization	6,900	3,878	1,110
Total Operating Expenses	43,622	35,964	29,184
Operating Income from Continuing Operations	32,700	20,006	898
Other Expense, net
Interest expense, net	(11,008)	(787)	(467)
Other income/(expense), net	41	160	(305)
Income from Continuing Operations Before (Provision)/Benefit for Income Taxes	21,733	19,379	126
(Provision)/Benefit for income taxes	(6,358)	9,368	(20)
Net Income from Continuing Operations	15,375	28,747	106
Discontinued Operation
Gain on discontinued operation, net of $38 provision for income taxes in the year ended December 31, 2013	0	0	195
Net Income	15,375	28,747	301
Computation of Income/(Loss) from Continuing Operations
Net Income from Continuing Operations	15,375	28,747	106
Preferred stock dividends	0	0	(4,975)
Income/(Loss) from Continuing Operations Attributable to Common Stockholders and Participating Securities	$ 15,375	$ 28,747	$ (4,869)
Basic Income/(Loss) Per Share:
Continuing operations (in dollars per share)	$ 1.34	$ 2.61	$ (0.96)
Discontinued operation (in dollars per share)	0	0	0.04
Basic Income/(Loss) Per Share	$ 1.34	$ 2.61	$ (0.92)
Basic Weighted-Average Shares Outstanding	11,370	10,941	5,071
Diluted Income/(Loss) Per Share:
Continuing operations (in dollars per share)	$ 1.32	$ 2.59	$ (0.96)
Discontinued operation (in dollars per share)	0	0	0.04
Diluted Income/(Loss) Per Share (in dollars per share)	$ 1.32	$ 2.59	$ (0.92)
Diluted Weighted-Average Shares Outstanding (in shares)	11,557	11,053	5,071

XML 18 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Earnings [Parenthetical] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Gain on discontinued operation, net of provision for income taxes	$ 0	$ 0	$ 38

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

XML 19 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Class C Special Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2012	$ (42,715)	$ 0	$ 0	$ 1,083	$ 0	$ (43,798)
Balance (in shares) at Dec. 31, 2012		4,070			0
Preferred Stock Dividends	(4,975)	$ 0	0	0	$ 0	(4,975)
Non-cash Compensation Relating to Business Combination	4,418	0	0	4,418	0	0
Cancellation of Convertible Preferred Stock	53,726	0	0	53,726	0	0
Shares Issued in Merger	29,795	$ 1	0	29,794	$ 0	0
Shares Issued in Merger (in shares)		5,469			0
Stock-based Compensation Expense	36	$ 0	0	36	$ 0	0
Purchase of Common Stock for Treasury	(433)	$ 0	0	0	$ (433)	0
Purchase of Common Stock for Treasury (in shares)		0			59
Issuance of Common Stock upon Warrant Exercise	809	$ 0	0	809	$ 0	0
Issuance of Common Stock upon Warrant Exercise (in shares)		90			0
Issuance of Restricted Stock Awards	0	$ 0	0	(365)	$ 365	0
Issuance of Restricted Stock Awards (in Shares)		0			(50)
Excess Tax Benefit from Stock-based Compensation Awards	0
Net Income	301	$ 0	0	0	$ 0	301
Balance at Dec. 31, 2013	40,962	$ 1	0	89,501	$ (68)	(48,472)
Balance (in shares) at Dec. 31, 2013		9,629			9
Stock-based Compensation Expense	3,423	$ 0	0	3,423	$ 0	0
Issuance of Common Stock upon Warrant Exercise	750	$ 0	0	750	$ 0	0
Issuance of Common Stock upon Warrant Exercise (in shares)		83			0
Issuance of Common Stock in Equity Offering	46,680	$ 0	0	46,680	$ 0	0
Issuance of Common Stock in Equity Offering (in shares)		1,613			0
Allocation of proceeds from sale of Convertible Notes to Embedded Conversion Option	20,195	$ 0	0	20,195	$ 0	0
Cost of Bond-hedge, Net of Proceeds from Sale of Warrant	(2,575)	0	0	(2,575)	0	0
Issuance of Common Shares upon Stock Option Exercise	819	$ 0	0	819	$ 0	0
Issuance of Common Shares upon Stock Option Exercise (in Shares)		43			0
Issuance of Restricted Stock Awards	0	$ 0	0	(68)	$ 68	0
Issuance of Restricted Stock Awards (in Shares)		20			(9)
Excess Tax Benefit from Stock-based Compensation Awards	784	$ 0	0	784	$ 0	0
Net Income	28,747	0	0	0	0	28,747
Balance at Dec. 31, 2014	139,785	$ 1	0	159,509	$ 0	(19,725)
Balance (in shares) at Dec. 31, 2014		11,388			0
Stock-based Compensation Expense	3,856	$ 0	0	3,856	$ 0	0
Purchase of Common Stock for Treasury	(113)	$ 0	0	0	$ (113)	0
Purchase of Common Stock for Treasury (in shares)		0			7
Issuance of Common Shares upon Stock Option Exercise	819	$ 0	0	706	$ 113	0
Issuance of Common Shares upon Stock Option Exercise (in Shares)		84			(5)
Issuance of Restricted Stock Awards	0	$ 0	0	0	$ 0	0
Issuance of Restricted Stock Awards (in Shares)		26			(2)
Excess Tax Benefit from Stock-based Compensation Awards	360	$ 0	0	360	$ 0	0
Net Income	15,375	0	0	0	0	15,375
Balance at Dec. 31, 2015	$ 160,082	$ 1	$ 0	$ 164,431	$ 0	$ (4,350)
Balance (in shares) at Dec. 31, 2015		11,498			0

XML 20 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net income	$ 15,375	$ 28,747	$ 301
Adjustments to reconcile net loss to net cash and cash equivalents provided by/(used in) operating activities:
Stock-based compensation	3,856	3,423	36
Deferred taxes	(1,877)	(14,459)	0
Depreciation and amortization	6,900	3,878	1,110
Loss on disposal of property and equipment	40	0	0
Non-cash interest relating to convertible notes and loan cost amortization	6,831	559	217
Non-cash compensation relating to business combination	0	0	4,418
Changes in operating assets and liabilities, net of those acquired in business combination:
Accounts receivable, net	(4,635)	(4,784)	(7,081)
Inventories, net	(5,869)	(3,468)	(708)
Prepaid expenses and other current assets	(314)	(558)	(188)
Accounts payable	(1,027)	225	(565)
Accrued compensation and related expenses	(160)	575	(2,854)
Current income taxes, net	(5,380)	4,233	20
Accrued Medicaid rebates	2,367	2,011	72
Accrued expenses, returned goods reserve and other	1,157	1,651	(67)
Net Cash and Cash Equivalents Provided by/(Used in) Continuing Operations	17,264	22,033	(5,289)
Net Cash Used in Discontinued Operation	0	0	(195)
Net Cash and Cash Equivalents Provided by/(Used in) Operating Activities	17,264	22,033	(5,484)
Cash Flows From Investing Activities
Cash acquired in business combination	0	0	18,198
Acquisition of product rights and other related assets	(30,500)	(34,634)	0
Release of restricted cash	0	0	2,260
Acquisition of property and equipment	(2,183)	(1,120)	(191)
Net Cash and Cash Equivalents (Used in)/Provided by Investing Activities	(32,683)	(35,754)	20,267
Cash Flows From Financing Activities
Net proceeds from equity offering	0	46,680	0
Net proceeds from convertible debt offering	0	138,243	0
Purchase of call option overlay, net	0	(15,623)	0
Repayment of line of credit, net	0	0	(4,065)
Proceeds from stock option exercises	819	819	0
Proceeds from warrant exercise	0	750	809
Excess tax benefit from share-based compensation awards	360	784	0
Treasury stock purchases	(113)	0	(433)
Net Cash and Cash Equivalents Provided by/(Used in) Financing Activities	1,066	171,653	(3,689)
Change in Cash and Cash Equivalents	(14,353)	157,932	11,094
Cash and cash equivalents, beginning of period	169,037	11,105	11
Cash and cash equivalents, end of period	154,684	169,037	11,105
Supplemental disclosure for cash flow information:
Cash paid for interest	4,205	0	250
Cash paid for income taxes, net	13,255	147	0
Supplemental non-cash investing and financing activities:
Property and equipment purchased and included in accounts payable	439	0	0
Issuance of common stock in connection with business combination	0	0	40,034
Cancellation of Series D, Series C, Series B, and Series A preferred stock	0	0	53,726
Acquired non-cash net assets	0	0	11,597
Preferred stock dividends accrued	$ 0	$ 0	$ 4,975

XML 21 R8.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2015

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Business

ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a specialty pharmaceutical company, developing and marketing generic and branded prescription products. ANI was organized as a Delaware corporation in April 2001. At our two facilities located in Baudette, Minnesota, which have a combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, we manufacture oral solid dose products, as well as liquids and topicals, including those that must be manufactured in a fully contained environment due to their potency. We also perform contract manufacturing for other pharmaceutical companies.

On June 19, 2013, BioSante Pharmaceuticals, Inc. (“BioSante”) acquired ANIP Acquisition Company (“ANIP”) in an all-stock, tax-free reorganization (the “Merger”) (Note 2), in which ANIP became a wholly-owned subsidiary of BioSante. BioSante was renamed ANI Pharmaceuticals, Inc. The Merger was accounted for as a reverse acquisition pursuant to which ANIP was considered the acquiring entity for accounting purposes. As such, ANIP's historical results of operations replace BioSante's historical results of operations for all periods prior to the Merger. The results of operations of both companies are included in our consolidated financial statements for all periods after completion of the Merger.

Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability and possible fluctuations in financial results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe the going-concern basis is appropriate for the accompanying consolidated financial statements based on our current operating plan and business strategy for the next 12 months.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior period information has been reclassified to conform to the current period presentation.

For the year ended December 31, 2015, we adopted new guidance regarding the presentation of the balance sheet disclosure for debt issuance costs and new guidance regarding the balance sheet classification of deferred taxes. We adopted these on a retrospective basis. To conform to the current period presentation, we reclassified the following amounts in our consolidated balance sheet dated December 31, 2014:

(in thousands)	Original Prior Period Presentation		Amount Reclassified		Current Prior Period Presentation
Deferred tax asset, net of valuation allowance, current	$	7,643	$	(7,643)	$	-
Prepaid expenses and other current assets	$	1,983	$	(844)	$	1,139
Current Assets	$	203,478	$	(8,487)	$	194,991
Deferred financing costs, net	$	3,307	$	(3,307)	$	-
Deferred tax asset, net of valuation allowance	$	7,796	$	7,643	$	15,439
Total Assets	$	263,709	$	(4,151)	$	259,558
Convertible notes, net of discount and deferred financing costs	$	110,691	$	(4,151)	$	106,540
Liabilities	$	123,924	$	(4,151)	$	119,773

Principles of Consolidation

The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, accruals for chargebacks, Medicaid rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, deferred taxes and valuation allowance, and the depreciable lives of long-lived assets. Actual results could differ from those estimates.

Comprehensive Income

We have no components of other comprehensive income and accordingly, no statement of comprehensive income is included in the accompanying consolidated financial statements.

Credit Concentration

Our customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.

During the year ended December 31, 2015, three customers represented approximately 26%, 20%, and 18% of net revenues, respectively. As of December 31, 2015, accounts receivable from these customers totaled 73% of net accounts receivable. During the year ended December 31, 2014, three customers represented approximately 30%, 25%, and 14% of net revenues, respectively. During the year ended December 31, 2013, three customers represented approximately 27%, 18%, and 10% of net revenues, respectively.

Vendor Concentration

We source the raw materials for its products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. As a result, we are dependent upon our current vendors to supply reliably the API required for ongoing product manufacturing. During the year ended December 31, 2015, we purchased approximately 33% of our inventory from two suppliers. As of December 31, 2015, amounts payable to these suppliers were immaterial. During the year ended December 31, 2014, we purchased approximately 42% of our inventory from two suppliers. During the year ended December 31, 2013, we purchased approximately 37% of our inventory from three suppliers.

Revenue Recognition

Revenue is recognized for product sales and contract manufacturing product sales upon passing of risk and title to the customer, when estimates of the selling price and discounts, rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments are reasonably determinable, collection is reasonably assured, and we have no further performance obligations. Contract manufacturing arrangements are typically less than two weeks in duration, and therefore the revenue is recognized upon completion of the aforementioned factors rather than using a proportional performance method of revenue recognition. The estimates for discounts, rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments reduce gross revenues to net revenues in the accompanying consolidated statements of earnings, and are presented as current liabilities or reductions in accounts receivable in the accompanying consolidated balance sheets (see “Accruals for Chargebacks, Rebates, Returns, and Other Allowances”). Historically, we have not entered into revenue arrangements with multiple elements.

Occasionally, we engage in contract services, which include product development services, laboratory services, and royalties on net sales of certain contract manufactured products. For these services, revenue is recognized according to the terms of the agreement with the customer, which sometimes include substantive, measurable risk-based milestones, and when we have a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured, and we have no further performance obligations under the agreement.

Cash and Cash Equivalents

We consider all highly liquid instruments with maturities of three months or less when purchased to be cash equivalents. All interest bearing and non-interest bearing accounts are guaranteed by the FDIC up to $250 thousand. The majority of our cash balances are in excess of FDIC coverage. We consider this to be a normal business risk.

In conjunction with the Merger, we acquired restricted cash, none of which remained at December 31, 2015 and 2014.

Accounts Receivable

We extend credit to customers on an unsecured basis. We use the allowance method to provide for doubtful accounts based on our evaluation of the collectability of accounts receivable, whereby we provide an allowance for doubtful accounts equal to the estimated uncollectible amounts. Our estimate is based on historical collection experience and a review of the current status of trade accounts receivable. We determine trade receivables to be delinquent when greater than 30 days past due. Receivables are written off when it is determined that amounts are uncollectible. We determined that no allowance for doubtful accounts was necessary as of December 31, 2015 and 2014.

Accruals for Chargebacks, Rebates, Returns and Other Allowances

Our generic and branded product revenues are typically subject to agreements with customers allowing chargebacks, Medicaid rebates, product returns, administrative fees, and other rebates and prompt payment discounts. We accrue for these items at the time of sale based on the estimates and methodologies described below. In the aggregate, these accruals exceed 50% of generic and branded gross product sales, reduce gross revenues to net revenues in the accompanying consolidated statements of earnings, and are presented as current liabilities or reductions in accounts receivable in the accompanying consolidated balance sheets. We continually monitor and re-evaluate the accruals as additional information becomes available, which includes, among other things, trade inventory levels, customer product mix, products returned by customers, and trends in Medicaid rebates experience. We make adjustments to the accruals at the end of each reporting period, to reflect any such updates to the relevant facts and circumstances. Accruals are relieved upon receipt of payment from or upon issuance of credit to the customer.

Chargebacks

Chargebacks, primarily from wholesalers, result from arrangements we have with indirect customers establishing prices for products which the indirect customer purchases through a wholesaler. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide a chargeback credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler's invoice price, typically Wholesale Acquisition Cost ("WAC").

Chargeback credits are calculated as follows:

Prior period chargebacks claimed by wholesalers are analyzed to determine the actual average selling price ("ASP") for each product. This calculation is performed by product by wholesaler. ASPs can be affected by several factors such as:

A change in customer mix

A change in negotiated terms with customers

A change in the volume of off-contract purchases

Changes in WAC

As necessary, we adjust ASPs based on anticipated changes in the factors above.

The difference between ASP and WAC is recorded as a reduction in both gross revenues in the consolidated statements of earnings and accounts receivable in the consolidated balance sheets, at the time we recognize revenue from the product sale.

To evaluate the adequacy of our chargeback accruals, we obtain on-hand inventory counts from the wholesalers. This inventory is multiplied by the chargeback amount, the difference between ASP and WAC, to arrive at total expected future chargebacks, which is then compared to the chargeback accruals. We continually monitor chargeback activity and adjust ASPs when we believe that actual selling prices will differ from current ASPs.

Medicaid Rebates

We participate in certain qualifying federal and state Medicaid rebate programs whereby discounts and rebates are provided to participating programs after the final dispensing of the product by a pharmacy to a Medicaid plan participant. Medicaid rebates are typically billed up to 120 days after the product is shipped. Medicaid rebate amounts per product unit are established by law, based on the Average Manufacturer Price (“AMP”), which is reported on a monthly and quarterly basis, and, in the case of branded products, best price, which is reported on a quarterly basis. Our Medicaid reserves are based on expected claims from state Medicaid programs. Estimates for expected claims are driven by patient usage, sales mix, calculated AMP or best price, as well as inventory in the distribution channel that will be subject to a Medicaid rebate. As a result of the delay between selling the products and rebate billing, our Medicaid rebate reserve includes both an estimate of outstanding claims for end-customer sales that occurred but for which the related claim has not been billed as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants.

To evaluate the adequacy of our Medicaid rebate reserve, we review the reserve on a quarterly basis against actual claims data to ensure the liability is fairly stated. We continually monitor our Medicaid rebate reserve and adjust our estimates if we believe that actual Medicaid rebates may differ from our established accruals. Accruals for Medicaid rebates are recorded as a reduction to gross revenues in the consolidated statements of earnings and as an increase to the Medicaid rebate reserve in the consolidated balance sheets.

Returns

We maintain a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date to up to one year after its expiration date. Our product returns are settled through the issuance of a credit to the customer. Our estimate for returns is based upon historical experience with actual returns. While such experience has allowed for reasonable estimation in the past, history may not always be an accurate indicator of future returns. We continually monitor our estimates for returns and make adjustments when we believe that actual product returns may differ from the established accruals. Accruals for returns are recorded as a reduction to gross revenues in the consolidated statements of earnings and as an increase to the return goods reserve in the consolidated balance sheets.

Administrative Fees and Other Rebates

Administrative fees or rebates are offered to wholesalers, group purchasing organizations and indirect customers. We accrue for fees and rebates, by product by wholesaler, at the time of sale based on contracted rates and ASPs.

To evaluate the adequacy of our administrative fee accruals, we obtain on-hand inventory counts from the wholesalers. This inventory is multiplied by the ASPs to arrive at total expected future sales, which is then multiplied by contracted rates. The result is then compared to the administrative fee accruals. We continually monitor administrative fee activity and adjust our accruals when we believe that actual administrative fees will differ from the accruals. Accruals for administrative fees and other rebates are recorded as a reduction in both gross revenues in the consolidated statements of earnings and accounts receivable in the consolidated balance sheets.

Prompt Payment Discounts

We often grant sales discounts for prompt payment. The reserve for prompt payment discounts is based on invoices outstanding. We assume, based on past experience, that all available discounts will be taken. Accruals for prompt payment discounts are recorded as a reduction in both gross revenues in the consolidated statements of earnings and accounts receivable in the consolidated balance sheets.

The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December 31, 2015, 2014, and 2013:

(in thousands)	Accruals for Chargebacks, Returns and Other Allowances
							Administrative		Prompt
			Medicaid				Fees and Other		Payment
	Chargebacks		Rebates		Returns		Rebates		Discounts
Balance at December 31, 2012	$	5,662	$	180	$	411	$	231	$	242
Accruals/Adjustments		28,009		333		1,595		2,355		1,129
Credits Taken Against Reserve		(29,595)		(260)		(1,270)		(1,851)		(1,039)
Balance at December 31, 2013	$	4,076	$	253	$	736	$	735	$	332
Accruals/Adjustments		35,740		2,692		1,493		5,212		1,820
Credits Taken Against Reserve		(32,951)		(681)		(784)		(4,460)		(1,681)
Balance at December 31, 2014	$	6,865	$	2,264	$	1,445	$	1,487	$	471
Accruals/Adjustments		51,933		6,719		2,808		6,136		2,744
Credits Taken Against Reserve		(47,417)		(4,352)		(1,605)		(5,970)		(2,541)
Balance at December 31, 2015	$	11,381	$	4,631	$	2,648	$	1,653	$	674

Inventories

Inventories consist of raw materials, packaging materials, work-in-progress, and finished goods. Inventories are stated at the lower of standard cost or net realizable value. We periodically review and adjust standard costs, which generally approximate weighted average cost.

Property and Equipment

Property and equipment are recorded at cost. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation is recorded on a straight-line basis over estimated useful lives as follows:

Buildings and improvements			20 - 40 years
Machinery, furniture and equipment			3 - 10 years

Construction in progress includes the cost of construction and other direct costs attributable to the construction, along with capitalized interest, if any. Depreciation is not recorded on construction in progress until such time as the assets are placed in service.

We review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment loss related to property and equipment was recognized during the years ended December 31, 2015, 2014, and 2013. Assets held for disposal are reportable at the lower of the carrying amount or fair value, less costs to sell. No assets were held for disposal as of December 31, 2015 and 2014.

Intangible Assets

Intangible assets were acquired as part of the Merger and several asset purchase transactions. These assets include ANDAs for a total of 54 previously marketed generic products we acquired in 2014 and 2015, product rights for our branded products Lithobid and Vancocin, the NDA for our male testosterone gel product, marketing and distribution rights related to an agreement with IDT Australia Limited, and fully amortized product rights for Reglan and a generic product. These intangible assets originally were recorded at fair value for business combinations and at relative fair value based on the purchase price for asset acquisitions and are stated net of accumulated amortization.

The ANDAs, NDAs, and rights are amortized over their remaining estimated useful lives, ranging from seven to 11 years, based on the straight-line method. Management reviews definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. No impairment loss related to intangibles was recognized in the years ended December 31, 2015, 2014, and 2013.

Goodwill

Goodwill relates to the Merger and represents the excess of the total purchase consideration over the fair value of acquired assets and assumed liabilities, using the purchase method of accounting. Goodwill is not amortized, but is subject to periodic review for impairment. Goodwill is reviewed annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying amount of the goodwill might not be recoverable. We perform our review of goodwill on our one reporting unit.

Before employing detailed impairment testing methodologies, we first evaluate the likelihood of impairment by considering qualitative factors relevant to our reporting unit. When performing the qualitative assessment, we evaluate events and circumstances that would affect the significant inputs used to determine the fair value of the goodwill. Events and circumstances evaluated include: macroeconomic conditions that could affect us, industry and market considerations for the generic pharmaceutical industry that could affect us, cost factors that could affect our performance, our financial performance (including share price), and consideration of any company-specific events that could negatively affect us, our business, or the fair value of our business. If we determine that it is more likely than not that goodwill is impaired, we will then apply detailed testing methodologies. Otherwise, we will conclude that no impairment has occurred.

Detailed impairment testing involves comparing the fair value of our one reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of ANI. If the fair value exceeds carrying value, then it is concluded that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second step is required to measure possible goodwill impairment loss. The second step includes hypothetically valuing the tangible and intangible assets and liabilities of our one reporting unit as if it had been acquired in a business combination. Then, the implied fair value of our one reporting unit's goodwill is compared to the carrying value of that goodwill. If the carrying value of our one reporting unit's goodwill exceeds the implied fair value of the goodwill, we recognize an impairment loss in an amount equal to the excess, not to exceed the carrying value. No impairment loss related to goodwill was recognized in the years ended December 31, 2015, 2014, and 2013.

Collaborative Arrangements

At times, we have entered into arrangements with various commercial partners to further business opportunities. In collaborative arrangements such as these, when we are actively involved and exposed to the risks and rewards of the activities and are determined to be the principal participant in the collaboration, we classify third party costs incurred and revenues in the consolidated statements of earnings on a gross basis. Otherwise, third party revenues and costs generated by collaborative arrangements are presented on a net basis. Payments between us and the other participants are recorded and classified based on the nature of the payments.

Research and Development Expenses

Research and development costs are expensed as incurred and primarily consist of expenses relating to product development. Research and development costs totaled $2.9 million, $2.7 million, and $1.7 million for the years ended December 31, 2015, 2014, and 2013, respectively.

Stock-Based Compensation

We have a stock-based compensation plan that includes stock options and restricted stock, which are awarded in exchange for employee and non-employee director services. We recognize the estimated fair value of stock-based awards and classify the expense where the underlying salaries are classified. We incurred $3.9 million, $3.4 million, and $36 thousand of non-cash, stock-based compensation cost for the years ended December 31, 2015, 2014, and 2013, respectively. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock is based on the closing market price of the stock at the grant date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.

Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of our stock price, dividend yields, future employee turnover rates, and future employee stock option exercise behaviors. Changes in these assumptions can affect the fair value estimate.

Income Taxes

We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. We calculate income tax benefits related to stock-based compensation arrangements using the with and without method.

We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and remain subject to examination by taxing jurisdictions for the years 1998 and all subsequent periods due to the availability of net operating loss carryforwards.

We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense. We did not have any such amounts accrued as of December 31, 2015, 2014, and 2013.

We consider potential tax effects resulting from discontinued operations and record intra-period tax allocations, when those effects are deemed material.

Earnings/(Loss) per Share

Basic earnings/(loss) per share is computed by dividing net income/(loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period.

Our unvested restricted shares and certain of our outstanding warrants contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted earnings/(loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and to the participating warrants, and excludes the impact of those shares from the denominator.

For purposes of determining diluted earnings/(loss) per share, we have elected a policy to assume that the principal portion of our 3.0% Convertible Senior Notes due December 1, 2019 (the “Notes,” Note 3) is settled in cash. As such, the principal portion of the Notes has no effect on either the numerator or denominator when determining diluted earnings/(loss) per share. Any conversion gain is assumed to be settled in shares and is incorporated in diluted earnings/(loss) per share using the treasury method. The warrants issued in conjunction with the issuance of the Notes are considered to be dilutive when they are in-the-money relative to our average stock price during the period; the bond hedge purchased in conjunction with the issuance of the Notes is always considered to be anti-dilutive.

For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, unvested restricted stock awards, stock purchase warrants, and any conversion gain on the Notes, using the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.

The numerator for earnings per share for the years ended December 31, 2015, 2014, and 2013 are calculated for basic and diluted earnings per share as follows:

	Basic						Diluted
(in thousands, except per share amounts)	Year ended December 31,						Year ended December 31,
	2015		2014		2013		2015		2014		2013
Net income	$	15,375	$	28,747	$	106	$	15,375	$	28,747	$	106
Preferred stock dividends		-		-		(4,975)		-		-		(4,975)
Net income allocated to restricted stock		(85)		(159)		-		(84)		(158)		-
Net income/(loss) from continuing operations allocated to common shares	$	15,290	$	28,588	$	(4,869)	$	15,291	$	28,589	$	(4,869)

Gain on discontinued operations	$	-	$	-	$	195	$	-	$	-	$	195
Net gain on discontinued operations allocated to warrants		-		-		(1)		-		-		(2)
Gain on discontinued operations allocated to common shares	$	-	$	-	$	194	$	-	$	-	$	193

Basic Weighted-Average Shares Outstanding		11,370		10,941		5,071		11,370		10,941		5,071
Dilutive effect of stock options								187		71		-
Dilutive effect of warrants								-		41		-
Diluted Weighted-Average Shares Outstanding								11,557		11,053		5,071

Earnings Per share from Continuing Operations	$	1.34	$	2.61	$	(0.96)	$	1.32	$	2.59	$	(0.96)
Earnings Per share from Discontinued Operation		-		-		0.04		-		-		0.04
Earnings/(Loss) Per Share	$	1.34	$	2.61	$	(0.92)	$	1.32	$	2.59	$	(0.92)

Anti-dilutive shares consist of out-of-the-money Class C Special stock, out-of-the-money common stock options, common stock options that are anti-dilutive when calculating the impact of the potential dilutive common shares using the treasury stock method, out-of-the-money warrants exercisable for common stock, and certain participating securities, if the effect of including both the income allocated to the participating security and the impact of the potential common shares would be anti-dilutive. The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings (loss) per share and which include the shares underlying the Notes, were 4.5 million, 4.7 million, and 2.7 million for the years ended December 31, 2015, 2014, and 2013.

Stock Splits and Other Reclassifications

In July 2013, our Board of Directors and stockholders approved a resolution to effect a one-for-six reverse stock split of our common stock and Class C Special stock with no corresponding change to the par values. The number of authorized shares of common stock, Class C Special stock and blank check preferred stock was reduced proportionally. Common stock and Class C Special stock for all periods presented have been adjusted retrospectively to reflect the one-for-six reverse stock split.

Fair Value of Financial Instruments

Our consolidated balance sheets include various financial instruments (primarily cash and cash equivalents, prepaid expenses, accounts receivable, accounts payable, accrued expenses, and other current liabilities) that are carried at cost and that approximate fair value. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues, or on the current rates we have been offered for debt of the same remaining maturities. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:

Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2—Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.

Level 3—Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

See Note 7 for additional information regarding fair value.

Segment Information

We currently operate in a single business segment.

Recent Accounting Pronouncements

In November 2015, the Financial Accounting Standards Board (“FASB”) issued guidance simplifying the balance sheet classification of deferred taxes. The new guidance requires that all deferred taxes be presented as noncurrent, rather than separated into current and noncurrent amounts. The guidance is effective for reporting periods beginning after December 15, 2016 and early adoption is permitted. In addition, the adoption of guidance can be applied either prospectively or retrospectively to all periods presented. We adopted this guidance for the year ended December 31, 2015 on a retrospective basis, and all periods are presented under this guidance. The adoption of this new guidance resulted in a reclassification of $7.6 million of current Deferred Tax Assets to noncurrent Deferred Tax Assets in our consolidated balance sheet as of December 31, 2014.

In July 2015, the FASB issued guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The guidance is effective for reporting periods beginning after December 15, 2016. The guidance should be applied prospectively, with earlier application permitted. We will adopt the guidance as of January 1, 2016, on a prospective basis. The adoption of this new guidance is not expected to have a material impact on our financial statements.

In April 2015, the FASB issued guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The guidance is effective for reporting periods beginning after December 15, 2015, and can be adopted on either a prospective or retrospective basis. We will adopt the guidance as of January 1, 2016, on a prospective basis. The adoption of this new guidance is not expected to have a material impact on our financial statements.

In April 2015, the FASB issued guidance to simplify the balance sheet disclosure for debt issuance costs. Under the guidance, debt issuance costs related to a recognized debt liability are presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The guidance is effective for reporting periods beginning after December 15, 2015 and must be adopted on a retrospective basis. Early adoption is permitted. We adopted this guidance for the year ended December 31, 2015 on a retrospective basis, and all periods are presented under this guidance. The adoption of this new guidance resulted in a reclassification of $0.8 million of Prepaid Expenses, a current asset, and $3.3 million of Deferred Loan Costs, a noncurrent asset, to the Convertible Debt current liability in our consolidated balance sheet as of December 31, 2014.

In May 2014, the FASB issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. We are currently evaluating the impact, if any, that this new accounting pronouncement will have on our financial statements.

We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on its consolidated results of operations, financial position, or cash flows.

XML 22 R9.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

BUSINESS COMBINATION

2. BUSINESS COMBINATION

On June 19, 2013, BioSante acquired ANIP in an all-stock, tax-free reorganization. Since the merger we have been operating under the leadership of the ANIP management team and ANIP's historical results of operations have replaced BioSante's historical results of operations for all periods prior to the Merger.

BioSante issued to ANIP stockholders shares of BioSante common stock such that the ANIP stockholders owned 57% of the combined company’s shares outstanding, and the former BioSante stockholders owned 43%. In addition, immediately prior to the Merger, BioSante distributed to its then current stockholders contingent value rights (“CVR”) providing payment rights arising from a future sale, transfer, license or similar transaction(s) involving BioSante’s LibiGel^® (female testosterone gel).

The Merger was accounted for as a reverse acquisition pursuant to which ANIP was considered the acquiring entity for accounting purposes. As such, ANIP's historical results of operations replace BioSante's historical results of operations for all periods prior to the Merger. BioSante, the accounting acquiree, was a publicly-traded pharmaceutical company focused on developing high value, medically-needed products. ANIP entered into the Merger to secure additional capital and gain access to capital market opportunities as a public company.

The results of operations of both companies are included in our consolidated financial statements for all periods after completion of the Merger.

Transaction Costs

In conjunction with the Merger, we incurred approximately $7.1 million in transaction costs, which were expensed in the periods in which they were incurred. These costs include:

Category	(in thousands)
Legal fees	$	1,227
Accounting fees		122
Consulting fees		119
Monitoring and advisory fees		390
Transaction bonuses		4,801
Other		429
Total transaction costs	$	7,088

Of the total expenses, $6.2 million was incurred and expensed in the year ended December 31, 2013, $5.5 million as selling, general, and administrative expense, $0.3 million as interest expense, and $0.4 million as other expense, in the accompanying consolidated statements of earnings. No transaction-related expenses were incurred in the year ended December 31, 2014 or 2015.

Purchase Consideration and Net Assets Acquired

The fair value of BioSante’s common stock used in determining the purchase price was $1.22 per share, the closing price on June 19, 2013, which resulted in a total purchase consideration of $29.8 million. The fair value of all additional consideration, including the vested BioSante stock options and CVRs, was immaterial. The following presents the final allocation of the purchase consideration to the assets acquired and liabilities assumed on June 19, 2013:

	(in thousands)
Total purchase consideration	$	29,795

Assets acquired
Cash and cash equivalents		18,198
Restricted cash		2,260
Testosterone Gel NDA⁽¹⁾		10,900
Other tangible assets		79
Deferred tax assets, net		-
Goodwill		1,838
Total assets		33,275
Liabilities assumed
Accrued severance		2,965
Other liabilities		515
Total liabilities		3,480
Total net assets acquired	$	29,795

⁽¹⁾

As part of the Merger, we acquired a testosterone gel product that was licensed to Teva (the "Testosterone Gel NDA"). In May 2015, we acquired from Teva the approved New Drug Application ("NDA") for the previously-licensed product (Note 6).

The Testosterone Gel NDA is being amortized on a straight-line basis over its estimated useful life of 11 years. Goodwill, which is not tax deductible since the transaction was structured as a tax-free exchange, is considered an indefinite-lived asset and relates primarily to intangible assets that do not qualify for separate recognition. As a result of purchase accounting related to the Merger, we established deferred tax assets of $9.6 million, deferred tax liabilities of $3.9 million, and a valuation allowance of $5.7 million, netting to deferred tax assets of $0.

Former BioSante operations generated no revenue and no expense in the year ended December 31, 2015 and 2014. Former BioSante operations generated $0.5 million of revenue in a non-recurring payment related to the testosterone gel NDA, and no expense from the acquisition date through December 31, 2013.

Pro Forma Condensed Combined Financial Information (unaudited)

The following unaudited pro forma condensed combined financial information summarizes the results of operations for 2013 as if the Merger had been completed as of January 1, 2012. Pro forma information reflects adjustments relating to (i) elimination of the interest on ANIP’s senior and equity-linked securities, (ii) elimination of monitoring and advisory fees payable to two ANIP investors, (iii) elimination of transaction costs, and (iv) amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the Merger had occurred as of January 1, 2012 or that may be obtained in the future.

(in thousands)	Year ended December 31,
	2013
Net revenues	$	30,228
Net income/(loss)	$	89

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 23 R10.htm IDEA: XBRL DOCUMENT

INDEBTEDNESS

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

INDEBTEDNESS

3. INDEBTEDNESS

Convertible Senior Notes

In December 2014, we issued $143.8 million of our Notes in a registered public offering. After deducting the underwriting discounts and commissions and other expenses (including the net cost of the bond hedge and warrant, discussed below), the net proceeds from the offering were approximately $122.6 million. The Notes pay 3.0% interest semi-annually in arrears on June 1 and December 1 of each year, starting on June 1, 2015, and are due December 1, 2019. The Notes are convertible into 2,068,792 shares of common stock, based on an initial conversion price of $69.48 per share.

The Notes are convertible at the option of the holder (i) during any calendar quarter beginning after March 31, 2015, if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five business days after any five consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of such period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; and (iii) on or after June 1, 2019 until the second scheduled trading day immediately preceding the maturity date.

Upon conversion by the holders, we may elect to settle such conversion in shares of our common stock, cash, or a combination thereof. As a result of our cash conversion option, we separately accounted for the value of the embedded conversion option as a debt discount (with an offset to APIC) of $33.6 million. The value of the embedded conversion option was determined based on the estimated fair value of the debt without the conversion feature, which was determined using market comparables to estimate the fair value of similar non-convertible debt (Note 7); the debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes.

Offering costs of $5.5 million were allocated to the debt and equity components in proportion to the allocation of proceeds to the components, as deferred financing costs and equity issuance costs, respectively. The deferred financing costs of $4.2 million are being amortized as additional non-cash interest expense using the straight-line method over the term of the debt, since this method was not significantly different from the effective interest method. Pursuant to guidance issued by the FASB in April 2015, we have classified the deferred financing costs as a direct deduction to the net carrying value of our Convertible Debt. The $1.3 million portion allocated to equity issuance costs was charged to APIC.

A portion of the offering proceeds was used to simultaneously enter into “bond hedge” (or purchased call) and “warrant” (or written call) transactions with an affiliate of one of the offering underwriters (collectively, the “Call Option Overlay”). We entered into the Call Option Overlay to synthetically raise the initial conversion price of the Notes to $96.21 per share and reduce the potential common stock dilution that may arise from the conversion of the Notes. The exercise price of the bond hedge is $69.48 per share, with an underlying 2,068,792 common shares; the exercise price of the warrant is $96.21 per share of our common stock, also with an underlying 2,068,792 common shares. Because the bond hedge and warrant are both indexed to our common stock and otherwise would be classified as equity, we recorded both elements as equity, resulting in a net reduction to APIC of $15.6 million.

The carrying value of the Notes is as follows as of December 31:

(in thousands)	2015		2014
Principal amount	$	143,750	$	143,750
Unamortized debt discount		(27,016)		(33,059)
Deferred financing costs		(3,307)		(4,151)
Net Carrying value	$	113,427	$	106,540

The following table sets forth the components of total interest expense related to the Notes recognized in the accompanying consolidated statements of earnings for the year ended December 31:

(in thousands)	2015		2014
Contractual coupon	$	4,312	$	252
Amortization of debt discount		6,043		489
Amortization of finance fees		844		70
Capitalized interest		(56)		-
	$	11,143	$	811

The effective interest rate on the Notes as of December 31, 2015 and 2014 was 7.8% and 7.7%, respectively, on an annualized basis.

XML 24 R11.htm IDEA: XBRL DOCUMENT

INVENTORIES

12 Months Ended

Dec. 31, 2015

INVENTORIES

INVENTORIES

4. INVENTORIES

Inventories consist of the following as of December 31:

(in thousands)		2015		2014
Raw materials	$	10,192	$	5,056
Packaging materials		998		794
Work-in-progress		456		411
Finished goods		1,897		1,368
		13,543		7,629
Reserve for excess/obsolete inventories		(156)		(111)
Inventories, net	$	13,387	$	7,518

XML 25 R12.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT, AND EQUIPMENT

5. PROPERTY, PLANT, AND EQUIPMENT

Property, Plant, and Equipment consist of the following as of December 31:

(in thousands)	2015		2014
Land	$	87	$	87
Buildings		3,682		3,682
Machinery, furniture and equipment		5,623		4,822
Construction in progress		2,189		426
		11,581		9,017
Less: accumulated depreciation		(4,450)		(3,794)
Property, Plant, and Equipment, net	$	7,131	$	5,223

Depreciation expense for the years ended December 31, 2015, 2014, and 2013 totaled $0.7 million, $0.6 million, and $0.5 million, respectively. During the year ended December 31, 2015, there was $56 thousand of interest capitalized into construction in progress. During the years ended December 31, 2014 and 2013, there was no material interest capitalized into construction in progress.

XML 26 R13.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2015

GOODWILL AND INTANGIBLE ASSETS

INTANGIBLE ASSETS

6. INTANGIBLE ASSETS

Goodwill

As a result of the Merger (Note 2), we recorded goodwill of $1.8 million in our one reporting unit. We assess the recoverability of the carrying value of goodwill on an annual basis as of October 31 of each year, and whenever events occur or circumstances changes that would, more likely than not, reduce the fair value of our reporting unit below its carrying value.

For the goodwill impairment analyses performed at October 31, 2015, 2014, and 2013, we performed qualitative assessments to determine whether it was more likely than not that our goodwill asset was impaired in order to determine the necessity of performing a quantitative impairment test, under which management would calculate the asset’s fair value. When performing the qualitative assessments, we evaluated events and circumstances that would affect the significant inputs used to determine the fair value of the goodwill. Events and circumstances evaluated include: macroeconomic conditions that could affect us, industry and market considerations for the generic pharmaceutical industry that could affect us, cost factors that could affect our performance, our financial performance (including share price), and consideration of any company-specific events that could negatively affect us, our business, or our fair value. Based on our assessments of the aforementioned factors, it was determined that it was more likely than not that the fair value of our one reporting unit is greater than its carrying amount as of October 31, 2015, 2014, and 2013, and therefore no quantitative testing for impairment was required.

In addition to the qualitative impairment analysis performed at October 31, 2015, there were no events or changes in circumstances that could have reduced the fair value of our reporting unit below its carrying value from October 31, 2015 to December 31, 2015. No impairment loss was recognized during the years ended December 31, 2015, 2014, and 2013, and the balance of goodwill was $1.8 million as of both December 31, 2015 and 2014.

Definite-lived Intangible Assets

Acquisition of Abbreviated New Drug Applications

On December 26, 2013, we entered into an agreement to purchase (the “Teva Purchase Agreement”) Abbreviated New Drug Applications (“ANDAs”) to produce 31 previously marketed generic drug products from Teva Pharmaceuticals (“Teva”) for $12.5 million in cash and a percentage of future gross profits from product sales. On January 2, 2014, we paid the first installment of $8.5 million to Teva and we paid the $4.0 million balance on March 6, 2014. The ANDAs are being amortized in full over their estimated useful lives of 10 years.

In March 2015 we purchased an ANDA from Teva for Flecainide, for $4.5 million in cash and a percentage of future gross profits from product sales. We accounted for this transaction as an asset purchase. The ANDA is being amortized in full over its estimated useful life of 10 years.

In July 2015, we purchased ANDAs for 22 previously marketed generic drug products from Teva for $25.0 million in cash and a percentage of future gross profits from product sales. We accounted for this transaction as an asset purchase. The ANDAs are being amortized in full over their estimated useful lives of 10 years.

Acquisition of Product Rights

In August 2014, we entered into an agreement to purchase (the “Vancocin Purchase Agreement”) the product rights to Vancocin from Shire ViroPharma Incorporated (“Shire”) for $11.0 million in cash. Pursuant to the terms of the Vancocin Purchase Agreement, we acquired the U.S. intellectual property rights and NDA associated with Vancocin, two related ANDAs, and certain equipment and inventory. The $10.5 million product rights intangible asset is being amortized over its estimated useful life of 10 years.

In July 2014, we entered into an agreement to purchase (the “Lithobid Purchase Agreement”) the product rights to Lithobid from Noven Therapeutics, LLC (“Noven”) for $11.0 million in cash at closing, and $1.0 million in cash if certain approvals were received from the FDA on or before June 30, 2015. This $1.0 million contingent payment was paid in January 2015. Pursuant to the terms of the Lithobid Purchase Agreement, we acquired the intellectual property rights and NDA associated with Lithobid, as well as a small amount of raw material inventory. The $12.0 million product rights intangible asset is being amortized over its estimated useful life of 10 years.

Testosterone Gel NDA

As part of our 2013 merger with BioSante, we acquired a testosterone gel product that was licensed to Teva (the “Testosterone Gel NDA”). In May 2015, we acquired from Teva the approved NDA for the previously-licensed product. Pursuant to the terms of the purchase agreement, upon commercialization, we will pay Teva a royalty of up to $5.0 million, at a rate of 5% of the consideration we receive as a result of commercial sale of the product. We assessed the value of the Testosterone Gel NDA under the new structure and determined that the asset was not impaired as of the May 2015 acquisition date. We will continue to assess the asset for potential impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no events or changes in circumstances during the period from the May 2015 acquisition date to December 31, 2015 that would indicate that the carrying amount may not be recoverable.

Marketing and Distribution Rights

In August 2015, we entered into a distribution agreement with IDT Australia Limited (“IDT”) to market several products in the U.S. (the “IDT Agreement”). The products, all of which are approved ANDAs, require various FDA filings and approvals prior to commercialization. In general, IDT will be responsible for regulatory submissions to the FDA and the manufacturing of certain products. We made an upfront payment to IDT of $1.0 million and will make additional milestone payments upon FDA approval for commercialization of certain products. Upon approval, IDT will manufacture some of the products and we will manufacture the other products. We will market and distribute all the products under our label in the United States, remitting a percentage of profits from sales of the drugs to IDT. The $1.0 million upfront payment was recorded as a marketing and distribution rights intangible asset and will be amortized in full over its estimated useful life of seven years.

The components of net definite-lived intangible assets are as follows:

(in thousands)	December 31, 2015				December 31, 2014				Weighted Average
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Amortization Period
Acquired ANDA intangible assets	$	42,076	$	(4,287)	$	12,577	$	(1,312)	10 years
Product rights		22,522		(3,277)		22,522		(1,133)	10 years
Testosterone gel NDA		10,900		(2,477)		10,900		(1,487)	11 years
Marketing and distribution rights		1,000		(60)		-		-	7 Years
	$	76,498	$	(10,101)	$	45,999	$	(3,932)

Definite-lived intangible assets are stated at cost, net of amortization using the straight line method over the expected useful lives of the intangible assets. Amortization expense was $6.2 million, $3.3 million, and $0.6 million for the years ended December 31, 2015, 2014, and 2013, respectively.

We test for impairment of definite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified in the years ended December 31, 2015, 2014, and 2013, and therefore no impairment loss was recognized during those periods.

Expected future amortization expense (Note 14) is as follows for the years ending December 31:

(in thousands)
2016	$	7,578
2017		7,578
2018		7,578
2019		7,578
2020		7,578
2021 and thereafter		28,507
Total	$	66,397

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 27 R14.htm IDEA: XBRL DOCUMENT

FAIR VALUE DISCLOSURES

12 Months Ended

Dec. 31, 2015

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES

7. FAIR VALUE DISCLOSURES

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. While our Notes are recorded on our consolidated balance sheets at their net carrying value of $113.4 million as of December 31, 2015, the Notes are being traded on the bond market and their full fair value is $144.5 million, based on their closing price on December 31, 2015, a Level 1 input.

Our CVRs (Note 2) are considered to be contingent consideration and are classified as liabilities. As such, the CVRs were recorded as purchase consideration at their estimated fair value, using Level 3 inputs, and are marked to market each reporting period until settlement. The fair value of CVRs is estimated using the present value of management’s projection of the expected payments pursuant to the terms of the CVR agreement, which is the primary unobservable input. If our projection or expected payments were to increase substantially, the value of the CVRs could increase as a result. The present value of the liability was calculated using a discount rate of 15%. We determined that the fair value of the CVRs was immaterial as of December 31, 2015 and 2014. We also determined that the changes in such fair value were immaterial for the years ended December 31, 2015, 2014, and the period from the date of the Merger to December 31, 2013.

Prior to the Merger, ANIP’s warrants to purchase common and preferred stock were classified as derivative liabilities and were measured at fair value using level 3 inputs. The fair value of stock purchase warrants was determined using a two-step process that included valuing ANIP's equity using both market and discounted cash flow methods, and then apportioning that value, using an equity allocation model, to each of ANIP's classes of stock. These models require the use of unobservable inputs such as fair value of ANIP's common and preferred stock, expected term, anticipated volatility, future interest and interest rates, expected cash flows and the number of outstanding common and preferred shares as of a future date. All such stock purchase warrants expired in connection with the Merger.

The following table presents our financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015 and 2014, by level within the fair value hierarchy:

(in thousands)

Description

Fair Value at
December 31, 2015

Level 1

Level 2

Level 3

Liabilities

CVRs

Description

Fair Value at
December 31, 2014

Level 1

Level 2

Level 3

Liabilities

CVRs

Financial Liabilities Measured at Fair Value on a Non-Recurring Basis

In December 2014, we issued $143.8M of Notes (Note 3). Because we have the option to cash settle the potential conversion of the Notes in cash, we separated the embedded conversion option feature from the debt feature and account for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical interest rate of 9%. The theoretical interest rate was determined from market comparables to estimate what the interest rate would have been if there was no conversion option embedded in the Notes. The fair value of the embedded conversion option was calculated using the residual value method and is classified as equity.

A portion of the offering proceeds was used to simultaneously enter into “bond hedge” (or purchased call) and “warrant” (or written call) transactions with an affiliate of one of the offering underwriters (Note 3). The exercise price of the bond hedge is $69.48 per share, with an underlying 2,068,792 common shares; the exercise price of the warrant is $96.21 per share of our common stock, also with an underlying 2,068,792 common shares. We calculated the fair value of the bond hedge based on the price we paid to purchase the call. We calculated the fair value of the warrant based on the price at which the affiliate purchased the warrants from us. Because the bond hedge and warrant are both indexed to our common stock and otherwise would be classified as equity, we recorded both elements as equity, resulting in a net reduction to APIC of $15.6 million.

Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

We measure our long-lived assets, including property, plant and equipment, intangible assets and goodwill, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. No such fair value impairment was recognized in the years ended December 31, 2015, 2014, and 2013.

Acquired Non-Financial Assets Measured at Fair Value

In July 2015, we purchased from Teva the ANDAs for 22 previously marketed generic drug products for $25.0 million in cash and a percentage of future gross profits from product sales (Note 6). The value of the ANDAs was based on the total purchase price of $25.0 million. In order to determine the fair value of the ANDAs, we used the present value of the estimated cash flows related to the product rights, using a discount rate of 10%. The $25.0 million of ANDAs will be amortized over their 10 year useful lives, and will be tested for impairment when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2015 and therefore no impairment loss was recognized in the year ended December 31, 2015.

In March 2015, we purchased from Teva the ANDA for Flecainide for $4.5 million in cash and a percentage of future gross profits from product sales (Note 6). The value of the ANDA was based on the purchase price of $4.5 million. In order to determine the fair value of the ANDA, we used the present value of the estimated cash flows related to the product rights, using a discount rate of 10%. The $4.5 million ANDA will be amortized over its 10 year useful life, and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2015 and therefore no impairment loss was recognized in the year ended December 31, 2015.

In August 2014, we acquired from Shire the U.S. product rights associated with Vancocin, certain equipment, and inventory, for total consideration of $11.0 million (Note 6). In addition, we capitalized $0.1 million of legal costs directly related to the transaction. These assets were recorded at their relative fair values, which were determined based on Level 3 unobservable inputs. In order to determine the fair value of the product rights, we used the present value of the estimated cash flows related to the product rights, using a discount rate of 10%. The $10.5 million of value assigned to the product rights will be amortized over their 10 year useful life, and will be tested for impairment when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2015 and therefore no impairment loss was recognized in the years ended December 31, 2014 and 2015. The $0.2 million of value assigned to the equipment was determined based on the amount for which we believe we would be able to sell the equipment. The equipment will be depreciated over its estimated 10 year useful life, and would be re-valued at the fair value if deemed to be other-than-temporarily impaired. We recorded $0.4 million of inventory. The value of the raw material inventory was determined based on the most recent purchase price of the material. The value of the finished goods inventory was determined based on the estimated sales to be generated from the finished goods, less costs to sell, including a reasonable margin.

In July 2014, we acquired from Noven the product rights associated with Lithobid, as well as a small amount of raw material inventory, for total consideration of $12.0 million (Note 6). In addition, we capitalized $45 thousand of legal costs directly related to the transaction. These assets were recorded at their relative fair values, which were determined based on Level 3 unobservable inputs. In order to determine the fair value of the product rights, we used the present value of the estimated cash flows related to the product rights, using a discount rate of 10%. The $12.0 million of ANDAs will be amortized over their 10 year useful life, and will be tested for impairment when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2015 and therefore no impairment loss was recognized in the years ended December 31, 2014 and 2015. We recorded $86 thousand of inventory. The value of the raw material inventory was determined based on the most recent purchase price of the material.

In the first quarter of 2014, we purchased from Teva the ANDAs for 31 previously marketed generic drug products for $12.5 million in cash and a percentage of future gross profits from product sales (Note 6). The value of the ANDAs was based on the total purchase price of $12.5 million. In order to determine the fair value of the ANDAs, we used the present value of the estimated cash flows related to the product rights, using a discount rate of 10%. The $12.5 million of ANDAs will be amortized over their 10 year useful lives, and will be tested for impairment when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2015 and therefore no impairment loss was recognized in the years ended December 31, 2014 and 2015.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 28 R15.htm IDEA: XBRL DOCUMENT

STOCKHOLDER'S EQUITY

12 Months Ended

Dec. 31, 2015

Stockholders Equity Note [Abstract]

SHAREHOLDER'S EQUITY

8. STOCKHOLDERS’ EQUITY

Authorized shares

We are authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at December 31, 2015.

There were 11.5 million and 11.4 million shares of common stock issued and outstanding as of December 31, 2015 and 2014, respectively.

There were 11 thousand shares of class C special stock issued and outstanding as of December 31, 2015 and 2014. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of our common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets if we were to liquidate, dissolve, or wind-up the company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption or sinking fund rights.

There were no shares of undesignated preferred stock outstanding as of December 31, 2015 and 2014.

Equity Offering

On March 10, 2014, we completed a follow-on public offering of 1.6 million shares of our common stock at a public offering price of $31.00 per share (the “March 2014 Offering”). We received gross proceeds of $50.0 million, or net proceeds of $46.7 million after deducting costs of $3.3 million, including the underwriters’ fees and commissions, as well as expenses directly related to the March 2014 Offering. The number of shares sold in the March 2014 Offering includes the exercise in full by the underwriters of their option to purchase an additional 0.2 million shares of common stock.

Stock Repurchase Program

In October 2015, our Board of Directors authorized a program to repurchase up to $25.0 million of our common stock. The authorization allows for repurchases to be conducted through open market or privately negotiated transactions through December 31, 2016. We did not purchase any of our common stock under this program in the year ended December 31, 2015 (Note 14). The stock repurchase program may be suspended, modified or discontinued at any time at our discretion.

Warrants

Warrants to purchase an aggregate of 2.1 million shares of our common stock were outstanding and exercisable as of December 31, 2015:

Issue Date	Number of Underlying Shares of Common Stock (in thousands)		Per Share Exercise Price		Expiration Date
December 4, 2014		1,799	$	96.21	March 1, 2020
December 5, 2014		270	$	96.21	March 1, 2020

All outstanding warrants are classified as equity. No warrants were issued or exercised during the year ended December 31, 2015. Warrants to purchase 405 thousand shares of common stock expired during the year ended December 31, 2015.

In December 2014, we issued 2.1 million warrants in conjunction with the issuance of the Notes (Note 3). In January 2014, warrants to purchase an aggregate of 20 thousand shares of common stock were exercised at $9.00 per share. In December 2014, warrants to purchase an aggregate of 63 thousand shares of common stock were exercised at $9.00 per share. Warrants to purchase an aggregate of 198 thousand shares of common stock expired unexercised during the year ended December 31, 2014.

We issued no warrants in the year ended December 31, 2013. In December 2013, warrants to purchase an aggregate of 90 thousand shares of common stock were exercised at $9.00 per share. Warrants to purchase an aggregate of 13 thousand shares of common stock expired unexercised during the year ended December 31, 2013.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 29 R16.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2015

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

9. STOCK-BASED COMPENSATION

All equity-based service awards are granted under the ANI Pharmaceuticals, Inc. Amended and Restated 2008 Stock Incentive Plan (the “2008 Plan”). As of December 31, 2015, 0.5 million shares of our common stock remained available for issuance under the 2008 Plan.

We measure the cost of equity-based service awards based on the grant-date fair value of the award. The cost is recognized over the period during which an employee is required to provide service in exchange for the award or the requisite service period. We recognize stock-based compensation expense ratably over the vesting periods of the awards, adjusted for estimated forfeitures.

The following table summarizes stock-based compensation expense included in our consolidated statements of earnings:

(in thousands)	Years ended December 31,
	2015		2014		2013
Cost of sales	$	82	$	104	$	-
Research and development	$	109	$	69	$	-
Selling, general, and administrative	$	3,665	$	3,250	$	36

Income tax benefits relating to $2.0 million and $4.4 million of stock-based compensation tax deductions were recognized in our 2015 and 2014 consolidated statements of earnings, respectively. No income tax benefit was recognized in our 2013 consolidated statements of earnings for stock-based compensation arrangements.

Stock Options

Outstanding stock options granted to employees generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one to three years and have 10-year contractual terms. Upon exercise of an option, we issue new shares of our common stock or issue shares from treasury stock.

For 2015, 2014, and 2013, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model, using the following weighted average assumptions:

	Years Ended December 31,
	2015		2014		2013
Expected option life (years)		5.50 - 6.25		5.39 - 6.25		6.25
Risk-free interest rate		1.31% - 1.82%		1.55% - 2.03%		1.72%
Expected stock price volatility		47.9% - 50.5%		50.6% - 55.1%		55.0%
Dividend yield		—		—		—

We use the simplified method to estimate the life of options. In 2014, 0.3 million options granted by the board of directors but requiring shareholder approval were approved at the May 22, 2014 shareholder’s meeting. As a result, the fair values of these options were calculated using the simplified method less the time between the grant date and the date of the approval, or 5.39 years. The risk-free interest rate used is the yield on a U.S. Treasury note as of the grant date with a maturity equal to the estimated life of the option. We calculated an estimated volatility rate based on the closing prices of several competitors that manufacture similar products. We have not issued a cash dividend in the past nor do we have any current plans to do so in the future; and therefore, an expected dividend yield of zero was used. Forfeitures are estimated at the time of grant and revised through a cumulative catch-up adjustment in the period of change if actual forfeitures differ from those estimates. For stock options granted during the years ended December 31, 2015, 2014, and 2013, we used an estimated forfeiture rate of zero for directors and officers and a forfeiture rate of 5.1% for non-officer employees.

On April 16, 2015, the Board of Directors approved grants of options to purchase 47 thousand shares of common stock to our officers and options to purchase 9 thousand shares of common stock to non-employee directors. On October 12, 2015, the Board of Directors approved a grant of options to purchase 3 thousand shares of common stock to our new board member.

On August 20, 2014, the Board of Directors approved a grant of options to purchase 25 thousand shares of common stock to one of our officers. On April 1, 2014, the Board of Directors approved grants of options to purchase 59 thousand shares of common stock to our officers and options to purchase 16 thousand shares of common stock to non-employee directors.

On July 12, 2013 and August 1, 2013, our Board of Directors approved grants to employees of stock options to purchase 0.3 million shares of ANI stock under the 2008 Plan, subject to shareholder approval of an increase in the total shares available for issuance under the 2008 Plan. The increase in total shares was approved by shareholders at the May 22, 2014 annual meeting, at which time we began recognizing stock-based compensation expense related to these awards.

In 2013, the Board of Directors granted options to purchase 21 thousand shares of common stock and 50 thousand shares of restricted stock to non-officer directors under the 2008 Plan.

A summary of stock option activity under the Plan during the years ended December 31, 2015, 2014, and 2013 is presented below:

							Weighted
					Weighted		Average
			Weighted		Average		Remaining
(in thousands, except per share	Option		Average		Grant-date		Term		Aggregate
and remaining term data)	Shares		Exercise Price		Fair Value		(years)		Intrinsic Value
Outstanding December 31, 2012		-	$	-				-	$	-
Net BioSante stock options assumed		99		59.59
Granted		21		6.36	$	3.40
Exercised		-		-						-
Forfeited or expired		-		-
Outstanding December 31, 2013		120	$	50.35				2.4	$	81
Granted		120		31.59	$	16.84
Options previously granted, approved by shareholders		325		6.39
Exercised		(43)		19.45						638
Forfeited		(4)		6.36
Expired		(60)		73.96
Outstanding December 31, 2014		458	$	14.44				8.7	$	19,472
Granted		138		62.07	$	30.08
Exercised		(89)		9.24						3,937
Forfeited		(33)		11.81
Expired		-		-
Outstanding December 31, 2015		474	$	29.40				8.2	$	10,136
Exercisable at December 31, 2015		101	$	17.97				7.4	$	3,069
Vested or expected to vest at December 31, 2015		464	$	29.06				8.2	$	10,046

As of December 31, 2015, there was $6.8 million of total unrecognized compensation cost related to non-vested stock options granted under the Plan. The cost is expected to be recognized over a weighted-average period of 2.4 years. During the year ended December 31, 2015, we received $0.8 million in cash from the exercise of stock options and recorded a $1.5 million tax benefit related to these exercises. During the year ended December 31, 2014, we received $0.8 million in cash from the exercise of stock options and recorded a $0.6 million tax benefit related to these exercises. During the year ended December 31, 2013, no options were exercised.

Restricted Stock Awards

On April 16, 2015, the Board of Directors approved grants of 24 thousand shares of restricted stock awards (“RSAs”) to the officers and 4 thousand to the non-officer directors. The RSAs granted to officers vest one-fourth per year, over four years on the anniversary of the grant date, provided that the officer continues to serve as an ANI employee on each of the vesting dates. The RSAs granted to non-officer directors vest over a one year period, provided that the grant recipient continues to serve as an ANI director on the vesting date. Shares of our common stock delivered to the officers and directors will be unrestricted upon vesting. During the vesting period, the recipient of the restricted stock has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant.

On April 1, 2014, the Board of Directors approved grants of 30 thousand shares of restricted stock to our officers. The restricted stock was granted subject to shareholder approval of an increase in the total restricted stock available for grant under the 2008 Plan. The increase in total restricted stock available for grant under the 2008 Plan was approved by shareholders at the May 22, 2014 annual meeting and the restricted stock was granted as of May 22, 2014. The RSAs vest one-fourth per year, over four years on the anniversary of the grant date, provided that the officer continues to serve as an ANI employee on each of the vesting dates. Shares of our common stock delivered to the officers will be unrestricted upon vesting. During the vesting period, the recipient of the restricted stock has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant.

On November 1, 2013, Board of Directors approved grants of 50 thousand restricted stock to the non-officer directors under the 2008 Plan. The RSAs vest one-third per year, over three years on the anniversary of the grant date, provided that the director continues to serve as an ANI director on each of the vesting dates. Shares of our common stock delivered to the directors will be unrestricted upon vesting. During the vesting period, the recipient of the restricted stock has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the director from the board prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant.

A summary of RSA activity under the Plan during the years ended December 31, 2015, 2014, and 2013 is presented below:

			Weighted
			Average Grant		Weighted Average
(in thousands, except per share			Date Fair		Remaining Term
and remaining term data)	Shares		Value		(years)
Unvested at December 31, 2012		-	$	-
Granted		50		10.20
Vested		-		-
Forfeited		-		-
Unvested at December 31, 2013		50	$	10.20		2.8
Granted		30		29.61
Vested		(17)		10.20
Forfeited		-		-
Unvested at December 31, 2014		63	$	19.34		2.6
Granted		28		67.26
Vested		(23)		15.82
Forfeited		(5)		19.41
Unvested at December 31, 2015		63	$	42.72		2.2

As of December 31, 2015, there was $2.1 million of total unrecognized compensation cost related to non-vested RSAs granted under the Plan, which is expected to be recognized over a weighted-average period of 2.2 years.

XML 30 R17.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Dec. 31, 2015

INCOME TAXES

INCOME TAXES

10. INCOME TAXES

Our total provision/(benefit) from income taxes consists of the following for the years ended December 31, 2015, 2014, and 2013:

(in thousands)	2015		2014		2013

Current income tax provision/(benefit):
Federal	$	7,264	$	4,034	$	20
State		611		273		-
Total		7,875		4,307		20

Deferred income tax (benefit)/provision:
Federal		(1,468)		2,113		635
State		(409)		154		(221)
Total		(1,877)		2,267		414

Change in valuation allowance		-		(16,726)		(414)
Excess tax benefit from stock-based compensation awards		360		784		-

Tax provision/(benefit) from continuing operations		6,358		(9,368)		20
Tax provision from discontinued operation		-		-		38
Total provision/(benefit) for income taxes	$	6,358	$	(9,368)	$	58

The difference between our expected income tax provision/(benefit) from applying federal statutory tax rates to the pre-tax income/(loss) from continuing operations and actual income tax provision/(benefit) from continuing operations relates primarily to the effect of the following:

	As of December 31,
	2015			2014			2013

US Federal statutory rate		35.0	%		35.0	%		35.0	%
State taxes, net of Federal benefit		2.1	%		1.0	%		1.0	%
Non-deductible expenses		0.1	%		-	%		245.9	%
Domestic production activities deduction		(5.3)	%		-	%		-	%
Change in valuation allowance		-	%		(86.5)	%		(300.4)	%
Change in tax rates and other		(1.6)	%		(1.2)	%		34.6	%
Stock-based compensation – windfall tax benefits		1.7	%		4.0	%		-	%
Other		(2.7)	%		(0.7)	%		-	%
Total income tax provision/(benefit)		29.3	%		(48.4)	%		16.1	%

Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Our deferred income tax assets and liabilities consisted of the following:

(in thousands)	As of December 31,
	2015		2014
Deferred tax assets:
Accruals and advances	$	2,153	$	2,149
Bond hedge		12,243		12,677
Accruals for chargebacks and returns		2,945		1,107
Inventory		1,271		618
Intangible Asset		504		-
Net operating loss carryforward		7,938		11,798
Other		1,149		674
Total deferred tax assets	$	28,203	$	29,023

Deferred tax liabilities:
Depreciation	$	(700)	$	(587)
Debt discount		(10,029)		(11,892)
Intangible assets		-		(467)
Other		(16)		(496)
Total deferred tax liabilities	$	(10,745)	$	(13,442)
Valuation allowance		(142)		(142)
Total deferred tax asset, net	$	17,316	$	15,439

As of December 31, 2015, we had Federal net operating loss carryforwards of approximately $21.7 million, which expire beginning in 2018, and a portion of which arose as a result of the Merger. The utilization of the net operating loss carryforwards are limited in future years as prescribed by Section 382 of the U.S. Internal Revenue Code; our current annual limitation of the Federal net operating loss is approximately $ 11.3 million per year.

We are required to establish a valuation allowance for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the projected future taxable income and tax planning strategies in making this assessment. As of both December 31, 2015 and 2014, we have provided a valuation allowance against certain state net operating loss carryforwards of approximately $0.1 million.

We are subject to income taxes in numerous jurisdictions in the U.S. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. We establish liabilities for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These liabilities are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these liabilities in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of changes to the liability that is considered appropriate. We identified no material uncertain tax positions as of December 31, 2015 and 2014.

We are subject to income tax audits in all jurisdictions for which we file tax returns. Tax audits by their nature are often complex and can require several years to complete. Neither ANI Pharmaceuticals, Inc. nor any of its subsidiaries is currently under audit in any jurisdiction. All of our income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.

XML 31 R18.htm IDEA: XBRL DOCUMENT

COLLABORATIVE ARRANGEMENTS

12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

COLLABORATIVE ARRANGEMENTS

11. COLLABORATIVE ARRANGEMENTS

RiconPharma LLC

In July 2011, we entered into a collaborative arrangement with RiconPharma LLC (“RiconPharma”). Under the parties' master product development and collaboration agreement (the “RiconPharma Agreement”), we and RiconPharma have agreed to collaborate in a cost, asset and profit sharing arrangement for the development, manufacturing, regulatory approval and marketing of certain pharmaceutical products in the United States.

In general, RiconPharma is responsible for developing the products and we are responsible for manufacturing, sales, marketing and distribution of the products. The parties are jointly responsible for directing any bioequivalence studies. We are responsible for obtaining and maintaining all necessary regulatory approvals, including the preparation of all ANDAs.

Under the RiconPharma Agreement and unless otherwise specified in an amendment, the parties will own equally all the rights, title and interest in the products. To the extent permitted by applicable law, we will be identified on the product packaging as the manufacturer and distributor of the product. During the term of the agreement, both parties are prohibited from developing, manufacturing, selling or distributing any products that are identical or bioequivalent to products covered under the RiconPharma Agreement.

We recognize the costs incurred with respect to this agreement as expense and classify the expenses based on the nature of the costs. In the year ended December 31, 2015, 2014, and 2013, we incurred $31 thousand, $0.4 million, and $0.7 million in research and development expenses related to the RiconPharma Agreement. No revenue has yet been recognized.

Sofgen Pharmaceuticals

August 2013 Sofgen Agreement

In August 2013, we entered into an agreement with Sofgen Pharmaceuticals (“Sofgen”) to develop an oral soft gel prescription product indicated for cardiovascular health (the “August 2013 Sofgen Agreement”). The product will be subject to an ANDA filing once developed. In general, Sofgen will be responsible for the development, manufacturing, and regulatory submission of the product, including preparation of the ANDA, and we will make payments based on the completion of certain milestones. Upon approval, Sofgen will manufacture the drug and we will market and distribute the product under our label in the United States, remitting a percentage of profits from sales of the drug to Sofgen.

Under the August 2013 Sofgen Agreement, Sofgen will own all the rights, title and interest in the products. During the term, both parties are prohibited from developing, manufacturing, selling, or distributing any product that is identical or bioequivalent to the product covered under the agreement in the U.S. The agreement may be terminated or amended under certain specified circumstances.

We recognize the costs incurred with respect to the August 2013 Sofgen Agreement as expense and classify the expenses based on the nature of the costs. In the years ended December 31, 2015, 2014, and 2013, we incurred $0.4 million, $0.2 million, and $0.2 million in research and development expenses related to the agreement. We recognized $7 thousand of net revenues related to the agreement in the year ended December 31, 2015.

April 2014 Sofgen Agreement

In April 2014, we entered into a second collaboration agreement with Sofgen to develop an oral soft gel prescription product (the “April 2014 Sofgen Agreement”). The product will be subject to an ANDA filing once developed. In general, Sofgen will be responsible for the development, manufacturing, and regulatory submission of the product, including preparation of the ANDA, and we will make payments based on the completion of certain milestones. Upon approval, Sofgen will manufacture the drug and we will market and distribute the product under our label in the United States, remitting a percentage of profits from sales of the drug to Sofgen.

Under the April 2014 Sofgen Agreement, Sofgen will own all the rights, title, and interest in the product. During the term, both parties are prohibited from developing, selling, or distributing any product in the United States that is identical or bioequivalent to the product covered under the agreement. The agreement can be terminated or amended under certain specified circumstances. The agreement’s initial term is ten years from the launch of the product, which term will automatically renew for two year terms until either party terminates the agreement.

We recognize the costs incurred with respect to the April 2014 Sofgen Agreement as expense and classify the expenses based on the nature of the costs. In the years ended December 31, 2015 and 2014, we incurred $37 thousand and $0.1 million in research and development expenses related to the agreement. No revenue has yet been recognized.

Dexcel Pharma Technologies Ltd

In June 2014, we entered into a collaboration agreement with Dexcel Pharma Technologies Ltd (“Dexcel”) to commercialize and sell a generic drug product (the “June 2014 Dexcel Agreement”). The product is subject to FDA approval of an ANDA filing. In general, Dexcel will be responsible for the manufacturing and regulatory submission of the product, including obtaining approval of the ANDA, and we will make payments based on the completion of certain milestones. Upon approval, Dexcel will manufacture the drug and we will market and distribute the product under our label in the United States, remitting a percentage of profits from sales of the drug to Dexcel.

Under the June 2014 Dexcel Agreement, Dexcel will own all the rights, title and interest in the product. During the term agreement, both parties are prohibited from developing, selling, or distributing any product in the United States that is identical or bioequivalent to the product covered under the agreement. The agreement can be terminated or amended under certain specified circumstances. The agreement’s initial term is five years from the launch of the product, which term can be renewed for two year terms if both parties agree, until either party terminates the agreement.

We recognize the costs incurred with respect to the June 2014 Dexcel Agreement as expense and classify the expenses based on the nature of the costs. We have not yet incurred any material expense related to the agreement and no revenue has yet been recognized.

XML 32 R19.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2015

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

12. COMMITMENTS AND CONTINGENCIES

Operating Leases

We lease equipment under operating leases that expire in May 2017 and September 2018. We also lease office space under operating leases that expire in February 2016 and September 2018. We do not intend to renew the lease that expires in February 2016.

For the annual periods after December 31, 2015, approximate minimum annual rental payments under non-cancelable leases are presented below:

(in thousands)
	Minimum
	Annual Rental
Year	Payments
2016	$	55
2017		46
2018		31
2019		-
2020		-
Thereafter		-
Total	$	132

In January 2016, we entered into a lease agreement beginning in March 2016 and ending in April 2021, averaging $3 thousand per month.

Rent expense for the years ended December 31, 2015, 2014, and 2013 totaled $74 thousand, $70 thousand, and $36 thousand, respectively.

Vendor Purchase Minimums

We have supply agreements with four vendors that include purchase minimums. Pursuant to these agreements, we will be required to purchase a total of $7.8 million of API from these four vendors during the year ended December 31, 2016.

Monitoring and Advisory Fees

Prior to the Merger, we were required to pay monitoring and advisory fees to two investors. A total of $0.5 million was included in other expense in the accompanying consolidated statements of earnings for the year ended December 31, 2013. These fees were paid quarterly in advance on the first business day of each calendar quarter.

Included in the $0.5 million above and in conjunction with the Merger, we paid additional monitoring and advisory fees totaling $0.4 million to the same two investors (Note 2). Upon completion of the Merger, our obligation to pay monitoring and advisory fees was terminated.

Government Regulation

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The Food and Drug Administration ("FDA"), in particular, maintains oversight of the formulation, manufacture, distribution, packaging and labeling of all of our products. The Drug Enforcement Administration ("DEA") maintains oversight over our products that are considered controlled substances.

Unapproved Products

Two of our products, Esterified Estrogen with Methyltestosterone (“EEMT”) and Opium Tincture, are marketed without approved New Drug Applications ("NDAs") or Abbreviated New Drug Applications ("ANDAs"). During the years ended December 31, 2015, 2014, and 2013, net revenues for these products totaled $44.3 million, $29.8 million, and $14.6 million, respectively.

The FDA's policy with respect to the continued marketing of unapproved products is stated in the FDA's September 2011 Compliance Policy Guide Sec. 440.100 titled “Marketed New Drugs without Approved NDAs or ANDAs.” Under this policy, the FDA has stated that it will follow a risk-based approach with regard to enforcement against such unapproved products. The FDA evaluates whether to initiate enforcement action on a case-by-case basis, but gives higher priority to enforcement action against products in certain categories, such as those marketed as unapproved drugs with potential safety risks or that lack evidence of effectiveness. We believe that, so long as we comply with applicable manufacturing standards, the FDA will not take action against us under the current enforcement policy. There can be no assurance, however, that the FDA will continue this policy or not take a contrary position with any individual product or group of products. If the FDA were to take a contrary position, we may be required to seek FDA approval for these products or withdraw such products from the market. If we decide to withdraw the products from the market, our net revenues for generic pharmaceutical products would decline materially, and if we decide to seek FDA approval, we would face increased expenses and might need to suspend sales of the products until such approval was obtained, and there are no assurances that we would receive such approval.

In addition, one group of products that we manufacture on behalf of a contract customer is marketed by that customer without an approved NDA. If the FDA took enforcement action against such customer, the customer may be required to seek FDA approval for the group of products or withdraw them from the market. Our contract manufacturing revenues for the group of unapproved products for the years ended December 31, 2015, 2014, and 2013 were $1.6 million, $1.2 million, and $2.0 million, respectively.

We received royalties on the net sales of a group of contract-manufactured products, which are marketed by the contract customer without an approved NDA. If the FDA took enforcement action against such customer, the customer may be required to seek FDA approval for the group of products or withdraw them from the market. Our royalties on the net sales of these unapproved products were $0.3 million for each of the three years ended December 31, 2015, 2014, and 2013.

Louisiana Medicaid Lawsuit

On September 11, 2013, the Attorney General of the State of Louisiana filed a lawsuit in Louisiana state court against numerous pharmaceutical companies, including us, under various state laws, alleging that each defendant caused the state’s Medicaid agency to provide reimbursement for drug products that allegedly were not approved by the FDA and therefore allegedly not reimbursable under the federal Medicaid program. The lawsuit relates to three cough and cold prescription products manufactured and sold by our former Gulfport, Mississippi operation, which was sold in September 2010. Through its lawsuit, the state seeks unspecified damages, statutory fines, penalties, attorneys’ fees and costs. While we cannot predict the outcome of the lawsuit at this time, we could be subject to material damages, penalties and fines. We intend to vigorously defend against all claims in the lawsuit.

Other Commitments and Contingencies

All manufacturers of the drug Reglan and its generic equivalent metoclopramide, including ANI, are facing allegations from plaintiffs in various states, including California, New Jersey, and Pennsylvania, claiming bodily injuries as a result of ingestion of metoclopramide or its brand name, Reglan, prior to the FDA's February 2009 Black Box warning requirement. In August 2012, we were dismissed with prejudice from all New Jersey cases. We consider our exposure to this litigation to be limited due to several factors: (1) the only generic metoclopramide that we manufactured prior to the implementation of the FDA's warning requirement was an oral solution introduced after May 28, 2008; (2) our market share for the oral solution was a very small portion of the overall metoclopramide market; and (3) once we received a request for change of labeling from the FDA, we submitted our proposed changes within 30 days, and such changes were subsequently approved by the FDA.

At the present time, we are unable to assess the likely outcome of the cases in the remaining states. Our insurance company has assumed the defense of this matter. We cannot provide assurances that the outcome of these matters will not have an adverse effect on our business, financial condition, and operating results. Furthermore, like all pharmaceutical manufacturers, we may be exposed to other product liability claims in the future, which could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results.

XML 33 R20.htm IDEA: XBRL DOCUMENT

QUARTERLY FINANCIAL DATA

12 Months Ended

Dec. 31, 2015

Quarterly Financial Data [Abstract]

QUARTERLY FINANCIAL DATA

13. QUARTERLY FINANCIAL DATA (unaudited)

The following table presents unaudited quarterly consolidated operating results for each of our last eight fiscal quarters. The information below has been prepared on a basis consistent with our audited consolidated financial statements.

	2015 Quarters (unaudited)
(in thousands, except per share data)	First		Second		Third		Fourth
Net revenues	$	18,799	$	19,516	$	19,972	$	18,035
Total operating expenses		9,232		11,102		11,521		11,767
Operating income from continuing operations		9,567		8,414		8,451		6,268
Net income from continuing operations	$	4,369	$	3,571	$	4,559	$	2,876
Basic and diluted income from continuing operations per share:
Basic income per share from continuing operations	$	0.38	$	0.31	$	0.40	$	0.25
Diluted incomeper share from continuing operations	$	0.38	$	0.31	$	0.39	$	0.25

	2014 Quarters (unaudited)
(in thousands, except per share data)	First		Second		Third		Fourth⁽¹⁾
Net revenues	$	10,899	$	6,647	$	17,387	$	21,037
Total operating expenses		7,404		9,107		9,188		10,265
Operating income/(loss) from continuing operations		3,495		(2,460)		8,199		10,772
Net income/(loss) from continuing operations	$	3,359	$	(2,363)	$	6,746	$	21,005
Basic and diluted income/(loss) from continuing operations per share:
Basic income/(loss) per share from continuing operations	$	0.33	$	(0.21)	$	0.59	$	1.85
Diluted income/(loss) per share from continuing operations	$	0.33	$	(0.21)	$	0.59	$	1.82

____________________________________________________________

⁽¹⁾ Net income from continuing operations, Basic income per share from continuing operations, and Diluted income per share from continuing operations for the fourth quarter of 2014 include the impact of an income tax benefit to reverse $16.7 million of the valuation allowance preiously recorded against our deferred tax assets.

XML 34 R21.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

SUBSEQUENT EVENT

14. SUBSEQUENT EVENTS

Purchase of Corticotropin and Corticotropin-Zinc NDAs

In September 2015, we entered into an asset purchase agreement with Merck Sharp & Dohme B.V. to purchase the right, title, and interest in the NDAs for Corticotropin and Corticotropin-Zinc, as well as associated product rights and manufacturing licenses, for $75.0 million in cash and a percentage of future net sales of the products under the NDAs. The asset acquisition closed in January 2016, and we made the $75.0 million cash payment using cash on hand. In addition, we capitalized $0.3 million of costs directly related to the transaction. The $75.3 million NDA assets will be amortized over their 10 year useful lives, and will be tested for impairment when events or circumstances indicate that the carrying value of the assets may not be recoverable.

Purchase of Distribution Rights and Early Stage Development Project

In January 2016, we entered into an agreement to purchase the exclusive U.S. distribution rights for three products from H2-Pharma, LLC, as well as an early stage development project for a generic injectable drug product, for $10.0 million in consideration.

Purchases under Stock Repurchase Program

In January 2016, we purchased 65 thousand shares for $2.5 million under our stock repurchase program, which program was authorized by our Board of Directors in October 2015.

XML 35 R22.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2015

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Business

Organization and Business

Basis of Presentation

Basis of Presentation

(in thousands)	Original Prior Period Presentation		Amount Reclassified		Current Prior Period Presentation
Deferred tax asset, net of valuation allowance, current	$	7,643	$	(7,643)	$	-
Prepaid expenses and other current assets	$	1,983	$	(844)	$	1,139
Current Assets	$	203,478	$	(8,487)	$	194,991
Deferred financing costs, net	$	3,307	$	(3,307)	$	-
Deferred tax asset, net of valuation allowance	$	7,796	$	7,643	$	15,439
Total Assets	$	263,709	$	(4,151)	$	259,558
Convertible notes, net of discount and deferred financing costs	$	110,691	$	(4,151)	$	106,540
Liabilities	$	123,924	$	(4,151)	$	119,773

Principles of consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

Use of Estimates

Use of Estimates

Comprehensive Income

Comprehensive Income

We have no components of other comprehensive income and accordingly, no statement of comprehensive income is included in the accompanying consolidated financial statements.

Credit Concentration

Credit Concentration

Our customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.

Vendor Concentration

Vendor Concentration

Revenue Recognition

Revenue Recognition

Cash and Cash Equivalents

Cash and Cash Equivalents

In conjunction with the Merger, we acquired restricted cash, none of which remained at December 31, 2015 and 2014.

Accounts Receivable

Accounts Receivable

Accruals for Chargebacks, Rebates, Returns and Other Allowances

Accruals for Chargebacks, Rebates, Returns and Other Allowances

Chargebacks

Chargeback credits are calculated as follows:

A change in customer mix

A change in negotiated terms with customers

A change in the volume of off-contract purchases

Changes in WAC

As necessary, we adjust ASPs based on anticipated changes in the factors above.

Medicaid Rebates

Returns

Administrative Fees and Other Rebates

Prompt Payment Discounts

The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December 31, 2015, 2014, and 2013:

(in thousands)	Accruals for Chargebacks, Returns and Other Allowances
							Administrative		Prompt
			Medicaid				Fees and Other		Payment
	Chargebacks		Rebates		Returns		Rebates		Discounts
Balance at December 31, 2012	$	5,662	$	180	$	411	$	231	$	242
Accruals/Adjustments		28,009		333		1,595		2,355		1,129
Credits Taken Against Reserve		(29,595)		(260)		(1,270)		(1,851)		(1,039)
Balance at December 31, 2013	$	4,076	$	253	$	736	$	735	$	332
Accruals/Adjustments		35,740		2,692		1,493		5,212		1,820
Credits Taken Against Reserve		(32,951)		(681)		(784)		(4,460)		(1,681)
Balance at December 31, 2014	$	6,865	$	2,264	$	1,445	$	1,487	$	471
Accruals/Adjustments		51,933		6,719		2,808		6,136		2,744
Credits Taken Against Reserve		(47,417)		(4,352)		(1,605)		(5,970)		(2,541)
Balance at December 31, 2015	$	11,381	$	4,631	$	2,648	$	1,653	$	674

Inventories

Inventories

Property and Equipment

Property and Equipment

Buildings and improvements			20 - 40 years
Machinery, furniture and equipment			3 - 10 years

Intangible Assets

Intangible Assets

Goodwill

Goodwill

Collaborative Arrangements

Collaborative Arrangements

Research and Development Expenses

Research and Development Expenses

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense. We did not have any such amounts accrued as of December 31, 2015, 2014, and 2013.

We consider potential tax effects resulting from discontinued operations and record intra-period tax allocations, when those effects are deemed material.

Earnings/(Loss) per Share

Earnings/(Loss) per Share

Basic earnings/(loss) per share is computed by dividing net income/(loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period.

The numerator for earnings per share for the years ended December 31, 2015, 2014, and 2013 are calculated for basic and diluted earnings per share as follows:

	Basic						Diluted
(in thousands, except per share amounts)	Year ended December 31,						Year ended December 31,
	2015		2014		2013		2015		2014		2013
Net income	$	15,375	$	28,747	$	106	$	15,375	$	28,747	$	106
Preferred stock dividends		-		-		(4,975)		-		-		(4,975)
Net income allocated to restricted stock		(85)		(159)		-		(84)		(158)		-
Net income/(loss) from continuing operations allocated to common shares	$	15,290	$	28,588	$	(4,869)	$	15,291	$	28,589	$	(4,869)

Gain on discontinued operations	$	-	$	-	$	195	$	-	$	-	$	195
Net gain on discontinued operations allocated to warrants		-		-		(1)		-		-		(2)
Gain on discontinued operations allocated to common shares	$	-	$	-	$	194	$	-	$	-	$	193

Basic Weighted-Average Shares Outstanding		11,370		10,941		5,071		11,370		10,941		5,071
Dilutive effect of stock options								187		71		-
Dilutive effect of warrants								-		41		-
Diluted Weighted-Average Shares Outstanding								11,557		11,053		5,071

Earnings Per share from Continuing Operations	$	1.34	$	2.61	$	(0.96)	$	1.32	$	2.59	$	(0.96)
Earnings Per share from Discontinued Operation		-		-		0.04		-		-		0.04
Earnings/(Loss) Per Share	$	1.34	$	2.61	$	(0.92)	$	1.32	$	2.59	$	(0.92)

Stock Splits and Other Reclassifications

Stock Splits and Other Reclassifications

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 2—Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.

Level 3—Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

See Note 7 for additional information regarding fair value.

Segment Information

Segment Information

We currently operate in a single business segment.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 36 R23.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2015

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule Of New Accounting Pronouncements And Changes In Accounting Principles

(in thousands)	Original Prior Period Presentation		Amount Reclassified		Current Prior Period Presentation
Deferred tax asset, net of valuation allowance, current	$	7,643	$	(7,643)	$	-
Prepaid expenses and other current assets	$	1,983	$	(844)	$	1,139
Current Assets	$	203,478	$	(8,487)	$	194,991
Deferred financing costs, net	$	3,307	$	(3,307)	$	-
Deferred tax asset, net of valuation allowance	$	7,796	$	7,643	$	15,439
Total Assets	$	263,709	$	(4,151)	$	259,558
Convertible notes, net of discount and deferred financing costs	$	110,691	$	(4,151)	$	106,540
Liabilities	$	123,924	$	(4,151)	$	119,773

Schedule of Valuation and Qualifying Accounts Disclosure

The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December 31, 2015, 2014, and 2013:

(in thousands)	Accruals for Chargebacks, Returns and Other Allowances
							Administrative		Prompt
			Medicaid				Fees and Other		Payment
	Chargebacks		Rebates		Returns		Rebates		Discounts
Balance at December 31, 2012	$	5,662	$	180	$	411	$	231	$	242
Accruals/Adjustments		28,009		333		1,595		2,355		1,129
Credits Taken Against Reserve		(29,595)		(260)		(1,270)		(1,851)		(1,039)
Balance at December 31, 2013	$	4,076	$	253	$	736	$	735	$	332
Accruals/Adjustments		35,740		2,692		1,493		5,212		1,820
Credits Taken Against Reserve		(32,951)		(681)		(784)		(4,460)		(1,681)
Balance at December 31, 2014	$	6,865	$	2,264	$	1,445	$	1,487	$	471
Accruals/Adjustments		51,933		6,719		2,808		6,136		2,744
Credits Taken Against Reserve		(47,417)		(4,352)		(1,605)		(5,970)		(2,541)
Balance at December 31, 2015	$	11,381	$	4,631	$	2,648	$	1,653	$	674

Schedule of Earnings Per Share, Basic and Diluted

The numerator for earnings per share for the years ended December 31, 2015, 2014, and 2013 are calculated for basic and diluted earnings per share as follows:

	Basic						Diluted
(in thousands, except per share amounts)	Year ended December 31,						Year ended December 31,
	2015		2014		2013		2015		2014		2013
Net income	$	15,375	$	28,747	$	106	$	15,375	$	28,747	$	106
Preferred stock dividends		-		-		(4,975)		-		-		(4,975)
Net income allocated to restricted stock		(85)		(159)		-		(84)		(158)		-
Net income/(loss) from continuing operations allocated to common shares	$	15,290	$	28,588	$	(4,869)	$	15,291	$	28,589	$	(4,869)

Gain on discontinued operations	$	-	$	-	$	195	$	-	$	-	$	195
Net gain on discontinued operations allocated to warrants		-		-		(1)		-		-		(2)
Gain on discontinued operations allocated to common shares	$	-	$	-	$	194	$	-	$	-	$	193

Basic Weighted-Average Shares Outstanding		11,370		10,941		5,071		11,370		10,941		5,071
Dilutive effect of stock options								187		71		-
Dilutive effect of warrants								-		41		-
Diluted Weighted-Average Shares Outstanding								11,557		11,053		5,071

Earnings Per share from Continuing Operations	$	1.34	$	2.61	$	(0.96)	$	1.32	$	2.59	$	(0.96)
Earnings Per share from Discontinued Operation		-		-		0.04		-		-		0.04
Earnings/(Loss) Per Share	$	1.34	$	2.61	$	(0.92)	$	1.32	$	2.59	$	(0.92)

- Definition

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

+ Details

XML 37 R24.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION (Tables)

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Business Combination Transaction Costs

In conjunction with the Merger, we incurred approximately $7.1 million in transaction costs, which were expensed in the periods in which they were incurred. These costs include:

Category	(in thousands)
Legal fees	$	1,227
Accounting fees		122
Consulting fees		119
Monitoring and advisory fees		390
Transaction bonuses		4,801
Other		429
Total transaction costs	$	7,088

Business Combination Purchase Price Allocation

The following presents the final allocation of the purchase consideration to the assets acquired and liabilities assumed on June 19, 2013:

	(in thousands)
Total purchase consideration	$	29,795

Assets acquired
Cash and cash equivalents		18,198
Restricted cash		2,260
Testosterone Gel NDA⁽¹⁾		10,900
Other tangible assets		79
Deferred tax assets, net		-
Goodwill		1,838
Total assets		33,275
Liabilities assumed
Accrued severance		2,965
Other liabilities		515
Total liabilities		3,480
Total net assets acquired	$	29,795

⁽¹⁾

Business Acquisition, Pro Forma Information

The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the Merger had occurred as of January 1, 2012 or that may be obtained in the future.

(in thousands)	Year ended December 31,
	2013
Net revenues	$	30,228
Net income/(loss)	$	89

XML 38 R25.htm IDEA: XBRL DOCUMENT

INDEBTEDNESS (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Convertible Debt

The carrying value of the Notes is as follows as of December 31:

(in thousands)	2015		2014
Principal amount	$	143,750	$	143,750
Unamortized debt discount		(27,016)		(33,059)
Deferred financing costs		(3,307)		(4,151)
Net Carrying value	$	113,427	$	106,540

Interest Income and Interest Expense Disclosure

The following table sets forth the components of total interest expense related to the Notes recognized in the accompanying consolidated statements of earnings for the year ended December 31:

(in thousands)	2015		2014
Contractual coupon	$	4,312	$	252
Amortization of debt discount		6,043		489
Amortization of finance fees		844		70
Capitalized interest		(56)		-
	$	11,143	$	811

XML 39 R26.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2015

INVENTORIES

Schedule of Inventory, Current

Inventories consist of the following as of December 31:

(in thousands)		2015		2014
Raw materials	$	10,192	$	5,056
Packaging materials		998		794
Work-in-progress		456		411
Finished goods		1,897		1,368
		13,543		7,629
Reserve for excess/obsolete inventories		(156)		(111)
Inventories, net	$	13,387	$	7,518

XML 40 R27.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, Plant, and Equipment consist of the following as of December 31:

(in thousands)	2015		2014
Land	$	87	$	87
Buildings		3,682		3,682
Machinery, furniture and equipment		5,623		4,822
Construction in progress		2,189		426
		11,581		9,017
Less: accumulated depreciation		(4,450)		(3,794)
Property, Plant, and Equipment, net	$	7,131	$	5,223

XML 41 R28.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2015

GOODWILL AND INTANGIBLE ASSETS

Schedule of Intangible Assets and Goodwill

The components of net definite-lived intangible assets are as follows:

(in thousands)	December 31, 2015				December 31, 2014				Weighted Average
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Amortization Period
Acquired ANDA intangible assets	$	42,076	$	(4,287)	$	12,577	$	(1,312)	10 years
Product rights		22,522		(3,277)		22,522		(1,133)	10 years
Testosterone gel NDA		10,900		(2,477)		10,900		(1,487)	11 years
Marketing and distribution rights		1,000		(60)		-		-	7 Years
	$	76,498	$	(10,101)	$	45,999	$	(3,932)

Finite-lived Intangible Assets Amortization Expense

Expected future amortization expense (Note 14) is as follows for the years ending December 31:

(in thousands)
2016	$	7,578
2017		7,578
2018		7,578
2019		7,578
2020		7,578
2021 and thereafter		28,507
Total	$	66,397

XML 42 R29.htm IDEA: XBRL DOCUMENT

FAIR VALUE DISCLOSURES (Tables)

12 Months Ended

Dec. 31, 2015

FAIR VALUE DISCLOSURES

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

(in thousands)

Description

Fair Value at
December 31, 2015

Level 1

Level 2

Level 3

Liabilities

CVRs

Description

Fair Value at
December 31, 2014

Level 1

Level 2

Level 3

Liabilities

CVRs

XML 43 R30.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders Equity Note [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights

Warrants to purchase an aggregate of 2.1 million shares of our common stock were outstanding and exercisable as of December 31, 2015:

Issue Date	Number of Underlying Shares of Common Stock (in thousands)		Per Share Exercise Price		Expiration Date
December 4, 2014		1,799	$	96.21	March 1, 2020
December 5, 2014		270	$	96.21	March 1, 2020

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 44 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2015

STOCK-BASED COMPENSATION

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The following table summarizes stock-based compensation expense included in our consolidated statements of earnings:

(in thousands)	Years ended December 31,
	2015		2014		2013
Cost of sales	$	82	$	104	$	-
Research and development	$	109	$	69	$	-
Selling, general, and administrative	$	3,665	$	3,250	$	36

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

For 2015, 2014, and 2013, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model, using the following weighted average assumptions:

	Years Ended December 31,
	2015		2014		2013
Expected option life (years)		5.50 - 6.25		5.39 - 6.25		6.25
Risk-free interest rate		1.31% - 1.82%		1.55% - 2.03%		1.72%
Expected stock price volatility		47.9% - 50.5%		50.6% - 55.1%		55.0%
Dividend yield		—		—		—

Schedule of Share-based Compansation, Stock Option And Restricted Stock, Activity

A summary of stock option activity under the Plan during the years ended December 31, 2015, 2014, and 2013 is presented below:

							Weighted
					Weighted		Average
			Weighted		Average		Remaining
(in thousands, except per share	Option		Average		Grant-date		Term		Aggregate
and remaining term data)	Shares		Exercise Price		Fair Value		(years)		Intrinsic Value
Outstanding December 31, 2012		-	$	-				-	$	-
Net BioSante stock options assumed		99		59.59
Granted		21		6.36	$	3.40
Exercised		-		-						-
Forfeited or expired		-		-
Outstanding December 31, 2013		120	$	50.35				2.4	$	81
Granted		120		31.59	$	16.84
Options previously granted, approved by shareholders		325		6.39
Exercised		(43)		19.45						638
Forfeited		(4)		6.36
Expired		(60)		73.96
Outstanding December 31, 2014		458	$	14.44				8.7	$	19,472
Granted		138		62.07	$	30.08
Exercised		(89)		9.24						3,937
Forfeited		(33)		11.81
Expired		-		-
Outstanding December 31, 2015		474	$	29.40				8.2	$	10,136
Exercisable at December 31, 2015		101	$	17.97				7.4	$	3,069
Vested or expected to vest at December 31, 2015		464	$	29.06				8.2	$	10,046

Nonvested Restricted Stock Shares Activity

A summary of RSA activity under the Plan during the years ended December 31, 2015, 2014, and 2013 is presented below:

			Weighted
			Average Grant		Weighted Average
(in thousands, except per share			Date Fair		Remaining Term
and remaining term data)	Shares		Value		(years)
Unvested at December 31, 2012		-	$	-
Granted		50		10.20
Vested		-		-
Forfeited		-		-
Unvested at December 31, 2013		50	$	10.20		2.8
Granted		30		29.61
Vested		(17)		10.20
Forfeited		-		-
Unvested at December 31, 2014		63	$	19.34		2.6
Granted		28		67.26
Vested		(23)		15.82
Forfeited		(5)		19.41
Unvested at December 31, 2015		63	$	42.72		2.2

XML 45 R32.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2015

INCOME TAXES

Schedule of Components of Income Tax Expense (Benefit)

Our total provision/(benefit) from income taxes consists of the following for the years ended December 31, 2015, 2014, and 2013:

(in thousands)	2015		2014		2013

Current income tax provision/(benefit):
Federal	$	7,264	$	4,034	$	20
State		611		273		-
Total		7,875		4,307		20

Deferred income tax (benefit)/provision:
Federal		(1,468)		2,113		635
State		(409)		154		(221)
Total		(1,877)		2,267		414

Change in valuation allowance		-		(16,726)		(414)
Excess tax benefit from stock-based compensation awards		360		784		-

Tax provision/(benefit) from continuing operations		6,358		(9,368)		20
Tax provision from discontinued operation		-		-		38
Total provision/(benefit) for income taxes	$	6,358	$	(9,368)	$	58

Schedule of Effective Income Tax Rate Reconciliation

	As of December 31,
	2015			2014			2013

US Federal statutory rate		35.0	%		35.0	%		35.0	%
State taxes, net of Federal benefit		2.1	%		1.0	%		1.0	%
Non-deductible expenses		0.1	%		-	%		245.9	%
Domestic production activities deduction		(5.3)	%		-	%		-	%
Change in valuation allowance		-	%		(86.5)	%		(300.4)	%
Change in tax rates and other		(1.6)	%		(1.2)	%		34.6	%
Stock-based compensation – windfall tax benefits		1.7	%		4.0	%		-	%
Other		(2.7)	%		(0.7)	%		-	%
Total income tax provision/(benefit)		29.3	%		(48.4)	%		16.1	%

Schedule of Deferred Tax Assets and Liabilities

(in thousands)	As of December 31,
	2015		2014
Deferred tax assets:
Accruals and advances	$	2,153	$	2,149
Bond hedge		12,243		12,677
Accruals for chargebacks and returns		2,945		1,107
Inventory		1,271		618
Intangible Asset		504		-
Net operating loss carryforward		7,938		11,798
Other		1,149		674
Total deferred tax assets	$	28,203	$	29,023

Deferred tax liabilities:
Depreciation	$	(700)	$	(587)
Debt discount		(10,029)		(11,892)
Intangible assets		-		(467)
Other		(16)		(496)
Total deferred tax liabilities	$	(10,745)	$	(13,442)
Valuation allowance		(142)		(142)
Total deferred tax asset, net	$	17,316	$	15,439

XML 46 R33.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2015

COMMITMENTS AND CONTINGENCIES

Operating Leases of Lessee Disclosure

For the annual periods after December 31, 2015, approximate minimum annual rental payments under non-cancelable leases are presented below:

(in thousands)
	Minimum
	Annual Rental
Year	Payments
2016	$	55
2017		46
2018		31
2019		-
2020		-
Thereafter		-
Total	$	132

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

XML 47 R34.htm IDEA: XBRL DOCUMENT

QUARTERLY FINANCIAL DATA (Tables)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

The information below has been prepared on a basis consistent with our audited consolidated financial statements.

	2015 Quarters (unaudited)
(in thousands, except per share data)	First		Second		Third		Fourth
Net revenues	$	18,799	$	19,516	$	19,972	$	18,035
Total operating expenses		9,232		11,102		11,521		11,767
Operating income from continuing operations		9,567		8,414		8,451		6,268
Net income from continuing operations	$	4,369	$	3,571	$	4,559	$	2,876
Basic and diluted income from continuing operations per share:
Basic income per share from continuing operations	$	0.38	$	0.31	$	0.40	$	0.25
Diluted incomeper share from continuing operations	$	0.38	$	0.31	$	0.39	$	0.25

	2014 Quarters (unaudited)
(in thousands, except per share data)	First		Second		Third		Fourth⁽¹⁾
Net revenues	$	10,899	$	6,647	$	17,387	$	21,037
Total operating expenses		7,404		9,107		9,188		10,265
Operating income/(loss) from continuing operations		3,495		(2,460)		8,199		10,772
Net income/(loss) from continuing operations	$	3,359	$	(2,363)	$	6,746	$	21,005
Basic and diluted income/(loss) from continuing operations per share:
Basic income/(loss) per share from continuing operations	$	0.33	$	(0.21)	$	0.59	$	1.85
Diluted income/(loss) per share from continuing operations	$	0.33	$	(0.21)	$	0.59	$	1.82

____________________________________________________________

XML 48 R35.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax asset, net of valuation allowance, current		$ 0
Prepaid expenses and other current assets		1,139
Current Assets	$ 192,583	194,991
Deferred financing costs, net		0
Deferred tax asset, net of valuation allowance	17,316	15,439
Total Assets	285,265	259,558
Convertible notes, net of discount and deferred financing costs	113,427	106,540
Liabilities	$ 125,183	119,773
Original Prior Period Presentation [Member]
Deferred tax asset, net of valuation allowance, current		7,643
Prepaid expenses and other current assets		1,983
Current Assets		203,478
Deferred financing costs, net		3,307
Deferred tax asset, net of valuation allowance		7,796
Total Assets		263,709
Convertible notes, net of discount and deferred financing costs		110,691
Liabilities		123,924
Amount Reclassified [Member]
Deferred tax asset, net of valuation allowance, current		(7,643)
Prepaid expenses and other current assets		(844)
Current Assets		(8,487)
Deferred financing costs, net		(3,307)
Deferred tax asset, net of valuation allowance		7,643
Total Assets		(4,151)
Convertible notes, net of discount and deferred financing costs		(4,151)
Liabilities		$ (4,151)

XML 49 R36.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 8,708
Ending balance	13,586	$ 8,708
Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	6,865	4,076	$ 5,662
Accruals/Adjustments	51,933	35,740	28,009
Credits Taken Against Reserve	(47,417)	(32,951)	(29,595)
Ending balance	11,381	6,865	4,076
Medicaid Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	2,264	253	180
Accruals/Adjustments	6,719	2,692	333
Credits Taken Against Reserve	(4,352)	(681)	(260)
Ending balance	4,631	2,264	253
Allowance for Sales Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	1,445	736	411
Accruals/Adjustments	2,808	1,493	1,595
Credits Taken Against Reserve	(1,605)	(784)	(1,270)
Ending balance	2,648	1,445	736
Administrative Fees And Other Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	1,487	735	231
Accruals/Adjustments	6,136	5,212	2,355
Credits Taken Against Reserve	(5,970)	(4,460)	(1,851)
Ending balance	1,653	1,487	735
Prompt Payment Discounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	471	332	242
Accruals/Adjustments	2,744	1,820	1,129
Credits Taken Against Reserve	(2,541)	(1,681)	(1,039)
Ending balance	$ 674	$ 471	$ 332

XML 50 R37.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

^[1]

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Net income, Basic

$ 2,876

$ 4,559

$ 3,571

$ 4,369

$ 21,005

$ 6,746

$ (2,363)

$ 3,359

$ 15,375

$ 28,747

$ 106

Preferred stock dividends

4,975

Net income/(loss) from continuing operations allocated to common shares, Basic

15,290

28,588

(4,869)

Gain on discontinued operations, Basic

195

Gain on discontinued operations allocated to common shares, Basic

$ 0

$ 194

Basic Weighted-Average Shares Outstanding

11,370

10,941

5,071

Earnings Per share from Continuing Operations, Basic

$ 1.34

$ 2.61

$ (0.96)

Earnings Per share from Discontinued Operation, Basic

0.04

Earnings/(Loss) Per Share

$ 0.25

$ 0.40

$ 0.31

$ 0.38

$ 1.85

$ 0.59

$ (0.21)

$ 0.33

$ 1.34

$ 2.61

$ (0.92)

Net income, Diluted

$ 2,876

$ 4,559

$ 3,571

$ 4,369

$ 21,005

$ 6,746

$ (2,363)

$ 3,359

$ 15,375

$ 28,747

$ 106

Preferred stock dividends, Diluted

4,975

Net income/(loss) from continuing operations allocated to common shares, Diluted

15,291

28,589

(4,869)

Gain on discontinued operations, Diluted

195

Gain on discontinued operations allocated to common shares, Diluted

$ 0

$ 193

Diluted Weighted-Average Shares Outstanding (in shares)

11,557

11,053

5,071

Earnings Per share from Continuing Operations, Diluted

$ 1.32

$ 2.59

$ (0.96)

Earnings Per share from Discontinued Operation, Diluted

0.04

Earnings/(Loss) Per Share, Diluted

$ 0.25

$ 0.39

$ 0.31

$ 0.38

$ 1.82

$ 0.59

$ (0.21)

$ 0.33

$ 1.32

$ 2.59

$ (0.92)

Equity Option [Member]

Dilutive effect

187

Warrant [Member]

Net income allocated to restricted stock, Basic

$ 0

$ (1)

Net gain on discontinued operations allocated, Diluted

$ 0

$ (2)

Dilutive effect

Restricted Stock [Member]

Net income allocated to restricted stock, Basic

$ (85)

$ (159)

$ 0

Net income allocated to restricted stock, Diluted

$ (84)

$ (158)

$ 0

[1]

Net income from continuing operations, Basic income per share from continuing operations, and Diluted income per share from continuing operations for the fourth quarter of 2014 include the impact of an income tax benefit to reverse $16.7 million of the valuation allowance preiously recorded against our deferred tax assets.

XML 51 R38.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fdic Guaranteed Amount	$ 250
Chargebacks And Other Accruals As Percent Of Gross Revenue	50.00%
Research and Development Expense, Total	$ 2,874	$ 2,678	$ 1,712
Allocated Share-based Compensation Expense	$ 3,900	$ 3,400	$ 36
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	3.00%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4.5	4.7	2.7
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent, Total	$ 17,316	$ 15,439
Prepaid Expense and Other Assets, Current		1,139
Deferred Finance Costs, Noncurrent, Net		0
Scenario, Adjustment [Member]
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent, Total		7,643
Prepaid Expense and Other Assets, Current		(844)
Deferred Finance Costs, Noncurrent, Net		$ (3,307)
Minimum [Member] \| Finite-Lived Intangible Assets [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	7 years
Maximum [Member] \| Finite-Lived Intangible Assets [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life	20 years
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life	40 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Customer One [Member]
Concentration Risk, Percentage	26.00%	30.00%	27.00%
Customer Two [Member]
Concentration Risk, Percentage	20.00%	25.00%	18.00%
Customer Three [Member]
Concentration Risk, Percentage	18.00%	14.00%	10.00%
Customer One Two And Three [Member]
Concentration Risk, Percentage	73.00%
Two Suppliers 2014 [Member]
Concentration Risk, Percentage		42.00%
Three Suppliers 2013 [Member]
Concentration Risk, Percentage			37.00%
Two Suppliers 2015 [Member]
Concentration Risk, Percentage	33.00%

XML 52 R39.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION (Details) $ in Thousands	Dec. 31, 2013 USD ($)
Transaction costs	$ 7,088
Legal Fees [Member]
Transaction costs	1,227
Accounting Fees [Member]
Transaction costs	122
Consulting Fees [Member]
Transaction costs	119
Monitoring And Advisory Fees [Member]
Transaction costs	390
Transaction Bonuses [Member]
Transaction costs	4,801
Others [Member]
Transaction costs	$ 429

XML 53 R40.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION (Details 1) - USD ($)
$ in Thousands

1 Months Ended

Jun. 19, 2013

Dec. 31, 2015

Dec. 31, 2014

Total purchase consideration

$ 29,795

Assets acquired

Cash and cash equivalents

18,198

Restricted cash

2,260

Testosterone Gel NDA

^[1]

10,900

Other tangible assets

Deferred tax assets, net

Goodwill

1,838

$ 1,838

Total assets

33,275

Liabilities assumed

Accrued severance

2,965

Other liabilities

515

Total liabilities

3,480

Total net assets acquired

$ 29,795

[1]	As part of the Merger, we acquired a testosterone gel product that was licensed to Teva (the "Testosterone Gel NDA"). In May 2015, we acquired from Teva the approved New Drug Application ("NDA") for the previously-licensed product (Note 6).

XML 54 R41.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION (Details 2) $ in Thousands	12 Months Ended
BUSINESS COMBINATION (Details 2) $ in Thousands	Dec. 31, 2013 USD ($)
Net revenues	$ 30,228
Net income/(loss)	$ 89

XML 55 R42.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATION (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

^[1]

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Jun. 19, 2013

Business Acquisition, Transaction Costs

$ 7,088

Business Combination, Acquisition Related Costs

6,200

Business Combination Cost Of Acquired Entity Purchase Price

$ 29,800

Share Price

$ 1.22

Business Combination Deferred Tax Assets Established Gross

$ 9,600

Business Combination Deferred Tax Liabilities Established Gross

3,900

Valuation allowance

5,700

Business Combination Purchase Price Allocation Deferred Tax Assets Net

Revenues, Total

$ 18,035

$ 19,972

$ 19,516

$ 18,799

$ 21,037

$ 17,387

$ 6,647

$ 10,899

$ 76,322

$ 55,970

30,082

Testosterone Gel NDA [Member]

Finite-Lived Intangible Asset, Useful Life

11 years

Selling, General and Administrative Expenses [Member]

Business Combination, Acquisition Related Costs

5,500

Interest Expense [Member]

Business Combination, Acquisition Related Costs

300

Other Expense [Member]

Business Combination, Acquisition Related Costs

400

BioSante Pharmaceuticals Inc [Member]

Business Acquisition, Percentage of Voting Interests Acquired

43.00%

Revenues, Total

$ 500

ANIP Acquisition Company [Member]

Business Acquisition, Percentage of Voting Interests Acquired

57.00%

[1]

XML 56 R43.htm IDEA: XBRL DOCUMENT

INDEBTEDNESS (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Principal amount	$ 143,750	$ 143,750
Unamortized debt discount	(27,016)	(33,059)
Deferred financing costs, net	(3,307)	(4,151)
Net Carrying value	$ 113,427	$ 106,540

XML 57 R44.htm IDEA: XBRL DOCUMENT

INDEBTEDNESS (Details 1) - USD ($) $ in Thousands	12 Months Ended
INDEBTEDNESS (Details 1) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Contractual coupon	$ 4,312	$ 252
Amortization of debt discount	6,043	489
Amortization of finance fees	844	70
Capitalized interest	(56)	0
Interest Expense, Debt	$ 11,143	$ 811

XML 58 R45.htm IDEA: XBRL DOCUMENT

INDEBTEDNESS (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares
Long-term Debt, Gross	$ 143,750	$ 143,750
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	3.00%
Debt Instrument, Unamortized Discount	$ 27,016	33,059
Amortization of Financing Costs	$ 844	70
Convertible Senior Notes [Member]
Long-term Debt, Gross		143,800
Proceeds from Issuance of Debt		$ 122,600
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate		3.00%
Underlying Shares Of Common Stock Convertible Debt \| shares		2,068,792
Debt Instrument, Convertible, Conversion Price \| $ / shares		$ 69.48
Debt Instrument, Convertible, Threshold Trading Days		20
Debt Instrument Percent Of Conversion Price		130.00%
Per Note Principal \| $ / shares		$ 1,000
Debt Instrument, Unamortized Discount		$ 33,600
Deferred Offering Costs		$ 5,500
Exercise Price Of Bond Hedge \| $ / shares		$ 69.48
Underlying Shares Of Common Stock Bond Hedge \| shares	2,068,792	2,068,792
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 96.21	$ 96.21
Net Adjustments To Additional Paid In Capital Bond Hedge Acquired Warrant Issued Net		$ 15,600
Debt Instrument, Interest Rate, Effective Percentage	7.80%	7.70%
Debt Instrument, Convertible, Threshold Consecutive Trading Days		30 days
Amortization of Financing Costs		$ 4,200
Payments of Stock Issuance Costs		$ 1,300

XML 59 R46.htm IDEA: XBRL DOCUMENT

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventories
Raw materials	$ 10,192	$ 5,056
Packaging materials	998	794
Work-in-progress	456	411
Finished goods	1,897	1,368
Inventory, Gross, Total	13,543	7,629
Reserve for excess/obsolete inventories	(156)	(111)
Inventories, net	$ 13,387	$ 7,518

XML 60 R47.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment, Gross, Total	$ 11,581	$ 9,017
Less: accumulated depreciation	(4,450)	(3,794)
Property, Plant, and Equipment, net	7,131	5,223
Land [Member]
Property, Plant and Equipment, Gross, Total	87	87
Buildings [Member]
Property, Plant and Equipment, Gross, Total	3,682	3,682
Machinery, furniture and equipment [Member]
Property, Plant and Equipment, Gross, Total	5,623	4,822
Construction in progress [Member]
Property, Plant and Equipment, Gross, Total	$ 2,189	$ 426

XML 61 R48.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Depreciation, Total	$ 700	$ 600	$ 500
Interest Costs Capitalized	$ 56

XML 62 R49.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Jul. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount				$ 76,498	$ 45,999
Accumulated Amortization				(10,101)	(3,932)
Acquired ANDA intangible assets
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount	$ 25,000	$ 4,500	$ 12,500	42,076	12,577
Accumulated Amortization				$ (4,287)	(1,312)
Weighted Average Amortization Period	10 years	10 years	10 years	10 years
Product rights
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount				$ 22,522	22,522
Accumulated Amortization				$ (3,277)	(1,133)
Weighted Average Amortization Period				10 years
Testosterone gel NDA
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount				$ 10,900	10,900
Accumulated Amortization				$ (2,477)	(1,487)
Weighted Average Amortization Period				11 years
Marketing and distribution rights
GOODWILL AND INTANGIBLE ASSETS
Gross Carrying Amount				$ 1,000	0
Accumulated Amortization				$ (60)	$ 0
Weighted Average Amortization Period				7 years

XML 63 R50.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details 1) $ in Thousands	Dec. 31, 2015 USD ($)
GOODWILL AND INTANGIBLE ASSETS
2016	$ 7,578
2017	7,578
2018	7,578
2019	7,578
2020	7,578
2021 and thereafter	28,507
Total	$ 66,397

XML 64 R51.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Textual) - USD ($) $ in Thousands			1 Months Ended					3 Months Ended	12 Months Ended
	Mar. 06, 2014	Jan. 02, 2014	Jul. 31, 2015	May. 31, 2015	Mar. 31, 2015	Aug. 31, 2014	Jul. 31, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 26, 2013	Jun. 19, 2013
GOODWILL AND INTANGIBLE ASSETS
Amortization of Intangible Assets									$ 6,200	$ 3,300	$ 600
Intangible Asset Purchase Agreement, Amount												$ 12,500
Payments to Acquire Intangible Assets									30,500	34,634	$ 0
Goodwill									1,838	1,838			$ 1,838
Finite-Lived Intangible Assets, Gross									$ 76,498	45,999
Intangible Asset Purchase Agreement Payment	$ 4,000	$ 8,500
Lithobid Purchase Agreement [Member]
GOODWILL AND INTANGIBLE ASSETS
Payments to Acquire Intangible Assets							$ 11,000
Finite-Lived Intangible Asset, Useful Life							10 years		10 years
Finite-Lived Intangible Assets, Gross							$ 12,000
Payment To Acquire Intangible Assets If Contingency Occurs							$ 1,000
Vancocin Purchase Agreement [Member]
GOODWILL AND INTANGIBLE ASSETS
Payments to Acquire Intangible Assets						$ 11,000
Finite-Lived Intangible Asset, Useful Life						10 years
Finite-Lived Intangible Assets, Gross						$ 10,500
Acquired ANDA Intangible Assets [Member]
GOODWILL AND INTANGIBLE ASSETS
Payments to Acquire Intangible Assets			$ 25,000		$ 4,500
Finite-Lived Intangible Asset, Useful Life			10 years		10 years			10 years	10 years
Finite-Lived Intangible Assets, Gross			$ 25,000		$ 4,500			$ 12,500	$ 42,076	12,577
Testosterone Gel NDA [Member]
GOODWILL AND INTANGIBLE ASSETS
Finite-Lived Intangible Asset, Useful Life									11 years
Maximum Royalties Potentially Payable				$ 5,000
Royalty Rate				5.00%
Finite-Lived Intangible Assets, Gross									$ 10,900	10,900
Marketing and Distribution Rights [Member]
GOODWILL AND INTANGIBLE ASSETS
Finite-Lived Intangible Asset, Useful Life									7 years
Finite-Lived Intangible Assets, Gross									$ 1,000	$ 0

XML 65 R52.htm IDEA: XBRL DOCUMENT

FAIR VALUE DISCLOSURES (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Liabilities
CVRs	$ 0	$ 0
Fair Value, Inputs, Level 1 [Member]
Liabilities
CVRs	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities
CVRs	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities
CVRs	$ 0	$ 0

XML 66 R53.htm IDEA: XBRL DOCUMENT

FAIR VALUE DISCLOSURES (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	12 Months Ended
	Jul. 31, 2015	Mar. 31, 2015	Aug. 31, 2014	Jul. 31, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate						15.00%
Payments to Acquire Intangible Assets						$ 30,500	$ 34,634	$ 0
Long-term Debt, Gross						143,750	143,750
Long-term Debt, Total						113,427	106,540
Finite-Lived Intangible Assets, Gross						76,498	45,999
Property, Plant and Equipment, Net, Total						7,131	5,223
Inventory, Net, Total						13,387	$ 7,518
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information
Theoretical Interest Rate For Debt Without Embedded Conversion Option							9.00%
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information
Notes Payable, Fair Value Disclosure						$ 144,500
Convertible Senior Notes [Member]
Fair Value Inputs, Assets, Quantitative Information
Long-term Debt, Gross							$ 143,800
Exercise Price Of Bond Hedge							$ 69.48
Underlying Shares Of Common Stock Bond Hedge						2,068,792	2,068,792
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 96.21	$ 96.21
Net Adjustments To Additional Paid In Capital Bond Hedge Acquired Warrant Issued Net							$ 15,600
Lithobid Purchase Agreement [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate				10.00%
Payments to Acquire Intangible Assets				$ 11,000
Finite-Lived Intangible Assets, Gross				$ 12,000
Finite-Lived Intangible Asset, Useful Life				10 years		10 years
Acquisition Costs Capitalized				$ 45
Inventory, Net, Total				$ 86
Vancocin Purchase Agreement [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			10.00%
Payments to Acquire Intangible Assets			$ 11,000
Finite-Lived Intangible Assets, Gross			$ 10,500
Finite-Lived Intangible Asset, Useful Life			10 years
Acquisition Costs Capitalized			$ 100
Property, Plant and Equipment, Net, Total			$ 200
Property, Plant and Equipment, Useful Life			10 years
Inventory, Net, Total			$ 400
Acquired ANDA Intangible Assets [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate	10.00%	10.00%			10.00%
Payments to Acquire Intangible Assets	$ 25,000	$ 4,500
Finite-Lived Intangible Assets, Gross	$ 25,000	$ 4,500			$ 12,500	$ 42,076	$ 12,577
Finite-Lived Intangible Asset, Useful Life	10 years	10 years			10 years	10 years

XML 67 R54.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) shares in Thousands	Dec. 31, 2015 $ / shares shares
Class of Warrant, Issued On December 4, 2014 - Expires March 1, 2020 [Member]
Number of Underlying Shares Of Common Stock \| shares	1,799
Per Share Exercise Price \| $ / shares	$ 96.21
Class of Warrant, Issued On December 5, 2014 - Expires March 1, 2020 [Member]
Number of Underlying Shares Of Common Stock \| shares	270
Per Share Exercise Price \| $ / shares	$ 96.21

XML 68 R55.htm IDEA: XBRL DOCUMENT

STOCKHOLDER'S EQUITY (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Mar. 10, 2014	Jan. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2015
Proceeds from Issuance of Common Stock, Net			$ 0	$ 46,680	$ 0
Preferred Stock, Shares Authorized			1,666,667	1,666,667
Stock Repurchase Program, Authorized Amount						$ 25,000
Preferred Stock, Par or Stated Value Per Share			$ 0.0001	$ 0.0001
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 9.00		$ 9.00	$ 9.00
Stock Issued During Period Due To Warrant Exercise Number		20,000		63,000	90,000
Stock Issued During Period Shares New Issues Due to Exercise of Option to Purchase Additional Shares				2,100,000
Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number			405,000	198,000	13,000
Class of Warrant or Right, Outstanding			2,100,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	1,600,000			1,613,000
Shares Issued, Price Per Share	$ 31.00
Proceeds from Issuance of Common Stock	$ 50,000
Proceeds from Issuance of Common Stock, Net	46,700
Payments of Stock Issuance Costs	$ 3,300
Stock Issued During Period Shares New Issues Due to Exercise of Option to Purchase Additional Shares	200,000
Common Stock, Shares Authorized			33,300,000
Common Stock, Par or Stated Value Per Share			$ 0.0001
Common Stock, Shares, Issued			11,500,000	11,500,000
Common Stock, Shares, Outstanding			11,400,000	11,400,000
Class C Special Stock [Member]
Common Stock, Shares Authorized			781,281	781,281
Common Stock, Par or Stated Value Per Share			$ 0.0001	$ 0.0001
Common Stock Conversion Price			$ 90.00
Common Stock, Shares, Issued			10,864	10,864
Common Stock, Shares, Outstanding			10,864	10,864
Undesignated Preferred Stock [Member]
Preferred Stock, Shares Authorized			1,700,000
Preferred Stock, Par or Stated Value Per Share			$ 0.0001

XML 69 R56.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	12 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allocated Share-based Compensation Expense	$ 3,900	$ 3,400	$ 36
Cost of Sales [Member]
Allocated Share-based Compensation Expense	82	104	0
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	109	69	0
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense	$ 3,665	$ 3,250	$ 36

XML 70 R57.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 1)	12 Months Ended
STOCK-BASED COMPENSATION (Details 1)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Expected option life (years)			6 years 3 months
Risk-free interest rate			1.72%
Expected stock price volatility			55.00%
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Expected option life (years)	5 years 6 months	5 years 4 months 20 days
Risk-free interest rate	1.31%	1.55%
Expected stock price volatility	47.90%	50.60%
Maximum [Member]
Expected option life (years)	6 years 3 months	6 years 3 months
Risk-free interest rate	1.82%	2.03%
Expected stock price volatility	50.50%	55.10%

XML 71 R58.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 2) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Option Shares
Options previously granted, approved by shareholders		300
Options [Member]
Option Shares
Outstanding at the beginning of the period (in shares)	458	120	0
Net BioSante stock options assumed			99
Granted (in shares)	138	120	21
Options previously granted, approved by shareholders		325
Exercised (in shares)	(89)	(43)	0
Forfeited (in shares)	(33)	(4)
Forfeited or expired (in shares)			0
Expired (in shares)	0	(60)
Outstanding at the end of the period (in shares)	474	458	120	0
Exercisable at the end of the period (in shares)	101
Vested or expected to vest at the end of the period (in shares)	464
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 14.44	$ 50.35	$ 0
Net BioSante stock options assumed (in dollars per share)			59.59
Granted (in dollars per share)	62.07	31.59	6.36
Options previously granted, approved by shareholders (in dollars per share)		6.39
Exercised (in dollars per share)	9.24	19.45	0
Forfeited (in dollars per share)	11.81	6.36
Forfeited or expired (in dollars per share)			0
Expired (in dollars per share)	0	73.96
Outstanding at the end of the period (in dollars per share)	29.40	14.44	50.35	$ 0
Exercisable at the end of the period (in dollars per share)	17.97
Vested or expected to vest at the end of the period (in dollars per share)	29.06
Weighted Average Grant-date Fair Value
Granted (in dollars per share)	$ 30.08	$ 16.84	$ 3.40
Weighted Average Remaining Term (Years)
Outstanding at the end of the period weighted average remaining term	8 years 2 months 12 days	8 years 8 months 12 days	2 years 4 months 24 days	0 years
Exercisable at the end of the period weighted average remaining term	7 years 4 months 24 days
Vested or expected to vest at the end of the period weighted average remaining term	8 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding at the beginning of the period intrinsic value (in dollars)	$ 19,472	$ 81	$ 0
Exercised at the end of the period intrinsic value (in dollars)	3,937	638	0
Outstanding at the end of the period intrinsic value (in dollars)	10,136	$ 19,472	$ 81	$ 0
Exercisable at the end of the period intrinsic value (in dollars)	3,069
Vested or expected to vest at the end of the period intrinsic value (in dollars)	$ 10,046

XML 72 R59.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 3) - Restricted Stock Awards [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unvested, Shares, Outstanding, Beginning of period	63	50	0
Unvested Shares, Granted	28	30	50
Unvested Shares, Vested	(23)	(17)	0
Unvested Shares, Forfeited	(5)	0	0
Unvested Shares, Outstanding, End of period	63	63	50
Weighted Average Grant Date Fair Value, Outstanding, Beginning of period	$ 19.34	$ 10.20	$ 0
Weighted Average Grant Date Fair Value, Granted	67.26	29.61	10.20
Weighted Average Grant Date Fair Value, Vested	15.82	10.20	0
Weighted Average Grant Date Fair Value, Forfeited	19.41	0	0
Weighted Average Grant Date Fair Value, Outstanding, End of period	$ 42.72	$ 19.34	$ 10.20
Weighted Average Remaining Term (in years)	2 years 2 months 12 days	2 years 7 months 6 days	2 years 9 months 18 days

XML 73 R60.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Textual) - USD ($) shares in Thousands, $ in Millions			1 Months Ended					12 Months Ended
	Oct. 12, 2015	Jul. 12, 2013	Apr. 16, 2015	Aug. 20, 2014	Apr. 30, 2014	Nov. 30, 2013	Aug. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant								500
Options Previously Granted Approved By Share holders									300
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense								$ 2.0	$ 4.4
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term										6 years 3 months
Non Officer Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate								5.10%	5.10%	5.10%
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Previously Granted Approved By Share holders		300					300
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			47	25	59					21
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options								$ 6.8
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								2 years 4 months 24 days
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options								$ 0.8	$ 0.8
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options								$ 1.5	$ 0.6
Non-Employee Director Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3		9		16
Options Previously Granted Approved By Shareholders [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term									5 years 4 months 20 days
2008 Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								2 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			24		30
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options								$ 2.1
2008 Plan [Member] \| Non-employee Director Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			4			50				50

XML 74 R61.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current income tax provision/(benefit):
Federal		$ 7,264	$ 4,034	$ 20
State		611	273	0
Total		7,875	4,307	20
Deferred income tax (benefit)/provision:
Federal		(1,468)	2,113	635
State		(409)	154	(221)
Total		(1,877)	2,267	414
Change in valuation allowance	$ (16,700)	0	(16,726)	(414)
Excess tax benefit from stock-based compensation awards		360	784	0
Tax provision/(benefit) from continuing operations		6,358	(9,368)	20
Tax provision from discontinued operation		0	0	38
Total provision/(benefit) for income taxes		$ 6,358	$ (9,368)	$ 58

XML 75 R62.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 1)	12 Months Ended
INCOME TAXES (Details 1)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
US Federal statutory rate	35.00%	35.00%	35.00%
State taxes, net of Federal benefit	2.10%	1.00%	1.00%
Non-deductible expenses	0.10%	0.00%	245.90%
Domestic production activities deduction	(5.30%)	0.00%	0.00%
Change in valuation allowance	0.00%	(86.50%)	(300.40%)
Change in tax rates and other	(1.60%)	(1.20%)	34.60%
Stock-based compensation - windfall tax benefits	1.70%	4.00%	0.00%
Other	(2.70%)	(0.70%)	0.00%
Total income tax provision/(benefit)	29.30%	(48.40%)	16.10%

XML 76 R63.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 2) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Accruals and advances	$ 2,153	$ 2,149
Bond hedge	12,243	12,677
Accruals for chargebacks and returns	2,945	1,107
Inventory	1,271	618
Intangible Asset	504	0
Net operating loss carryforward	7,938	11,798
Other	1,149	674
Total deferred tax assets	28,203	29,023
Deferred tax liabilities:
Depreciation	(700)	(587)
Debt discount	(10,029)	(11,892)
Intangible assets	0	(467)
Other	(16)	(496)
Total deferred tax liabilities	(10,745)	(13,442)
Valuation allowance	(142)	(142)
Total deferred tax asset, net	$ 17,316	$ 15,439

XML 77 R64.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Textual) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets, Valuation Allowance	$ 142	$ 142
Operating Loss Carryforwards	$ 21,700
Operating Loss Carryforwards, Limitations on Use	approximately $11.3 million per year

XML 78 R65.htm IDEA: XBRL DOCUMENT

COLLABORATIVE ARRANGEMENTS (Details Textual) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

^[1]

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Research and Development Expense, Total

$ 2,874

$ 2,678

$ 1,712

Revenues

$ 18,035

$ 19,972

$ 19,516

$ 18,799

$ 21,037

$ 17,387

$ 6,647

$ 10,899

76,322

55,970

30,082

Riconpharma LLC [Member]

Research and Development Expense, Total

400

700

Sofgen Pharmaceuticals [Member] | August 2013 Sofgen Agreement [Member]

Research and Development Expense, Total

400

200

$ 200

Revenues

Sofgen Pharmaceuticals [Member] | April 2014 Sofgen Agreement [Member]

Research and Development Expense, Total

$ 37

$ 100

[1]

XML 79 R66.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Dec. 31, 2015 USD ($)
2016	$ 55
2017	46
2018	31
2019	0
2020	0
Thereafter	0
Total	$ 132

XML 80 R67.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES
Operating Leases, Rent Expense			$ 74	$ 70	$ 36
Monitoring And Advisory Fee			500		500
Monitoring And Advisory Fee In Conjunction With Business Combination					400
Subsequent Event [Member]
COMMITMENTS AND CONTINGENCIES
Operating Leases, Rent Expense	$ 3
Subsequent Event [Member] \| Four Vendors [Member]
COMMITMENTS AND CONTINGENCIES
Long-term Purchase Commitment, Amount		$ 7,800
Unapproved Products [Member]
COMMITMENTS AND CONTINGENCIES
Revenue, Net			44,300	29,800	14,600
Unapproved Products [Member] \| Contract Customer [Member]
COMMITMENTS AND CONTINGENCIES
Revenue, Net			1,600	1,200	2,000
Royalty Revenue, Total			$ 300	$ 300	$ 300

XML 81 R68.htm IDEA: XBRL DOCUMENT

QUARTERLY FINANCIAL DATA (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

^[1]

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Net revenues

$ 18,035

$ 19,972

$ 19,516

$ 18,799

$ 21,037

$ 17,387

$ 6,647

$ 10,899

$ 76,322

$ 55,970

$ 30,082

Total operating expenses

11,767

11,521

11,102

9,232

10,265

9,188

9,107

7,404

43,622

35,964

29,184

Operating income/(loss) from continuing operations

6,268

8,451

8,414

9,567

10,772

8,199

(2,460)

3,495

32,700

20,006

898

Net Income from Continuing Operations

$ 2,876

$ 4,559

$ 3,571

$ 4,369

$ 21,005

$ 6,746

$ (2,363)

$ 3,359

$ 15,375

$ 28,747

$ 106

Basic and diluted income/(loss) from continuing operations per share:

Basic income/(loss) per share from continuing operations (in dollars per share)

$ 0.25

$ 0.40

$ 0.31

$ 0.38

$ 1.85

$ 0.59

$ (0.21)

$ 0.33

$ 1.34

$ 2.61

$ (0.92)

Diluted income/(loss) per share from continuing operations (in dollars per share)

$ 0.25

$ 0.39

$ 0.31

$ 0.38

$ 1.82

$ 0.59

$ (0.21)

$ 0.33

$ 1.32

$ 2.59

$ (0.92)

[1]

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

XML 82 R69.htm IDEA: XBRL DOCUMENT

QUARTERLY FINANCIAL DATA (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 16,700	$ 0	$ 16,726	$ 414

XML 83 R70.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Textual) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets		$ 30,500	$ 34,634	$ 0
Finite-Lived Intangible Assets, Gross		$ 76,498	$ 45,999
Subsequent Event [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets	$ 10,000
Stock Repurchased During Period, Shares	65
Stock Repurchased During Period, Value	$ 2,500
Corticotropin and Corticotropin-Zinc NDAs [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets	$ 75,000
Finite-Lived Intangible Assets, Remaining Amortization Period	10 years
Acquisition Costs Capitalized	$ 300
Finite-Lived Intangible Assets, Gross	$ 75,300

EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 85 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 266 403 1 true 78 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.biosantepharma.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.biosantepharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Consolidated Balance Sheets [Parenthetical] Sheet http://www.biosantepharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Consolidated Statements of Earnings Sheet http://www.biosantepharma.com/role/ConsolidatedStatementsOfEarnings Consolidated Statements of Earnings Statements 4 false false R5.htm 105 - Statement - Consolidated Statements of Earnings [Parenthetical] Sheet http://www.biosantepharma.com/role/ConsolidatedStatementsOfEarningsParenthetical Consolidated Statements of Earnings [Parenthetical] Statements 5 false false R6.htm 106 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.biosantepharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 107 - Statement - Consolidated Statements of Cash Flows Sheet http://www.biosantepharma.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 108 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 109 - Disclosure - BUSINESS COMBINATION Sheet http://www.biosantepharma.com/role/BusinessCombination BUSINESS COMBINATION Notes 9 false false R10.htm 110 - Disclosure - INDEBTEDNESS Sheet http://www.biosantepharma.com/role/Indebtedness INDEBTEDNESS Notes 10 false false R11.htm 111 - Disclosure - INVENTORIES Sheet http://www.biosantepharma.com/role/Inventories INVENTORIES Notes 11 false false R12.htm 112 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT Sheet http://www.biosantepharma.com/role/PropertyPlantAndEquipment PROPERTY, PLANT, AND EQUIPMENT Notes 12 false false R13.htm 113 - Disclosure - INTANGIBLE ASSETS Sheet http://www.biosantepharma.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 13 false false R14.htm 114 - Disclosure - FAIR VALUE DISCLOSURES Sheet http://www.biosantepharma.com/role/FairValueDisclosures FAIR VALUE DISCLOSURES Notes 14 false false R15.htm 115 - Disclosure - STOCKHOLDER'S EQUITY Sheet http://www.biosantepharma.com/role/StockholdersEquity STOCKHOLDER'S EQUITY Notes 15 false false R16.htm 116 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.biosantepharma.com/role/StockbasedCompensation STOCK-BASED COMPENSATION Notes 16 false false R17.htm 117 - Disclosure - INCOME TAXES Sheet http://www.biosantepharma.com/role/IncomeTaxes INCOME TAXES Notes 17 false false R18.htm 118 - Disclosure - COLLABORATIVE ARRANGEMENTS Sheet http://www.biosantepharma.com/role/CollaborativeArrangements COLLABORATIVE ARRANGEMENTS Notes 18 false false R19.htm 119 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.biosantepharma.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 120 - Disclosure - QUARTERLY FINANCIAL DATA Sheet http://www.biosantepharma.com/role/QuarterlyFinancialData QUARTERLY FINANCIAL DATA Notes 20 false false R21.htm 121 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.biosantepharma.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 21 false false R22.htm 122 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 123 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 124 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://www.biosantepharma.com/role/BusinessCombinationTables BUSINESS COMBINATION (Tables) Tables http://www.biosantepharma.com/role/BusinessCombination 24 false false R25.htm 125 - Disclosure - INDEBTEDNESS (Tables) Sheet http://www.biosantepharma.com/role/IndebtednessTables INDEBTEDNESS (Tables) Tables http://www.biosantepharma.com/role/Indebtedness 25 false false R26.htm 126 - Disclosure - INVENTORIES (Tables) Sheet http://www.biosantepharma.com/role/InventoriesTables INVENTORIES (Tables) Tables http://www.biosantepharma.com/role/Inventories 26 false false R27.htm 127 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) Sheet http://www.biosantepharma.com/role/PropertyPlantAndEquipmentTables PROPERTY, PLANT, AND EQUIPMENT (Tables) Tables http://www.biosantepharma.com/role/PropertyPlantAndEquipment 27 false false R28.htm 128 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.biosantepharma.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://www.biosantepharma.com/role/IntangibleAssets 28 false false R29.htm 129 - Disclosure - FAIR VALUE DISCLOSURES (Tables) Sheet http://www.biosantepharma.com/role/FairValueDisclosuresTables FAIR VALUE DISCLOSURES (Tables) Tables http://www.biosantepharma.com/role/FairValueDisclosures 29 false false R30.htm 130 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.biosantepharma.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables 30 false false R31.htm 131 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.biosantepharma.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.biosantepharma.com/role/StockbasedCompensation 31 false false R32.htm 132 - Disclosure - INCOME TAXES (Tables) Sheet http://www.biosantepharma.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.biosantepharma.com/role/IncomeTaxes 32 false false R33.htm 133 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.biosantepharma.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.biosantepharma.com/role/CommitmentsAndContingencies 33 false false R34.htm 134 - Disclosure - QUARTERLY FINANCIAL DATA (Tables) Sheet http://www.biosantepharma.com/role/QuarterlyFinancialDataTables QUARTERLY FINANCIAL DATA (Tables) Tables http://www.biosantepharma.com/role/QuarterlyFinancialData 34 false false R35.htm 135 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 35 false false R36.htm 136 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1 DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 137 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails2 DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) Details http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 37 false false R38.htm 138 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Details http://www.biosantepharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 38 false false R39.htm 139 - Disclosure - BUSINESS COMBINATION (Details) Sheet http://www.biosantepharma.com/role/BusinessCombinationDetails BUSINESS COMBINATION (Details) Details http://www.biosantepharma.com/role/BusinessCombinationTables 39 false false R40.htm 140 - Disclosure - BUSINESS COMBINATION (Details 1) Sheet http://www.biosantepharma.com/role/BusinessCombinationDetails1 BUSINESS COMBINATION (Details 1) Details http://www.biosantepharma.com/role/BusinessCombinationTables 40 false false R41.htm 141 - Disclosure - BUSINESS COMBINATION (Details 2) Sheet http://www.biosantepharma.com/role/BusinessCombinationDetails2 BUSINESS COMBINATION (Details 2) Details http://www.biosantepharma.com/role/BusinessCombinationTables 41 false false R42.htm 142 - Disclosure - BUSINESS COMBINATION (Details Textual) Sheet http://www.biosantepharma.com/role/BusinessCombinationDetailsTextual BUSINESS COMBINATION (Details Textual) Details http://www.biosantepharma.com/role/BusinessCombinationTables 42 false false R43.htm 143 - Disclosure - INDEBTEDNESS (Details) Sheet http://www.biosantepharma.com/role/IndebtednessDetails INDEBTEDNESS (Details) Details http://www.biosantepharma.com/role/IndebtednessTables 43 false false R44.htm 144 - Disclosure - INDEBTEDNESS (Details 1) Sheet http://www.biosantepharma.com/role/IndebtednessDetails1 INDEBTEDNESS (Details 1) Details http://www.biosantepharma.com/role/IndebtednessTables 44 false false R45.htm 145 - Disclosure - INDEBTEDNESS (Details Textual) Sheet http://www.biosantepharma.com/role/IndebtednessDetailsTextual INDEBTEDNESS (Details Textual) Details http://www.biosantepharma.com/role/IndebtednessTables 45 false false R46.htm 146 - Disclosure - INVENTORIES (Details) Sheet http://www.biosantepharma.com/role/InventoriesDetails INVENTORIES (Details) Details http://www.biosantepharma.com/role/InventoriesTables 46 false false R47.htm 147 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) Sheet http://www.biosantepharma.com/role/PropertyPlantAndEquipmentDetails PROPERTY, PLANT, AND EQUIPMENT (Details) Details http://www.biosantepharma.com/role/PropertyPlantAndEquipmentTables 47 false false R48.htm 148 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details Textual) Sheet http://www.biosantepharma.com/role/PropertyPlantAndEquipmentDetailsTextual PROPERTY, PLANT, AND EQUIPMENT (Details Textual) Details http://www.biosantepharma.com/role/PropertyPlantAndEquipmentTables 48 false false R49.htm 149 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://www.biosantepharma.com/role/IntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://www.biosantepharma.com/role/IntangibleAssetsTables 49 false false R50.htm 150 - Disclosure - INTANGIBLE ASSETS (Details 1) Sheet http://www.biosantepharma.com/role/IntangibleAssetsDetails1 INTANGIBLE ASSETS (Details 1) Details http://www.biosantepharma.com/role/IntangibleAssetsTables 50 false false R51.htm 151 - Disclosure - INTANGIBLE ASSETS (Details Textual) Sheet http://www.biosantepharma.com/role/IntangibleAssetsDetailsTextual INTANGIBLE ASSETS (Details Textual) Details http://www.biosantepharma.com/role/IntangibleAssetsTables 51 false false R52.htm 152 - Disclosure - FAIR VALUE DISCLOSURES (Details) Sheet http://www.biosantepharma.com/role/FairValueDisclosuresDetails FAIR VALUE DISCLOSURES (Details) Details http://www.biosantepharma.com/role/FairValueDisclosuresTables 52 false false R53.htm 153 - Disclosure - FAIR VALUE DISCLOSURES (Details Textual) Sheet http://www.biosantepharma.com/role/FairValueDisclosuresDetailsTextual FAIR VALUE DISCLOSURES (Details Textual) Details http://www.biosantepharma.com/role/FairValueDisclosuresTables 53 false false R54.htm 154 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.biosantepharma.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.biosantepharma.com/role/StockholdersEquityTables 54 false false R55.htm 155 - Disclosure - STOCKHOLDER'S EQUITY (Details Textual) Sheet http://www.biosantepharma.com/role/StockholdersEquityDetailsTextual STOCKHOLDER'S EQUITY (Details Textual) Details http://www.biosantepharma.com/role/StockholdersEquity 55 false false R56.htm 156 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.biosantepharma.com/role/StockbasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.biosantepharma.com/role/StockbasedCompensationTables 56 false false R57.htm 157 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://www.biosantepharma.com/role/StockbasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://www.biosantepharma.com/role/StockbasedCompensationTables 57 false false R58.htm 158 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://www.biosantepharma.com/role/StockbasedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://www.biosantepharma.com/role/StockbasedCompensationTables 58 false false R59.htm 159 - Disclosure - STOCK-BASED COMPENSATION (Details 3) Sheet http://www.biosantepharma.com/role/StockbasedCompensationDetails3 STOCK-BASED COMPENSATION (Details 3) Details http://www.biosantepharma.com/role/StockbasedCompensationTables 59 false false R60.htm 160 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) Sheet http://www.biosantepharma.com/role/StockbasedCompensationDetailsTextual STOCK-BASED COMPENSATION (Details Textual) Details http://www.biosantepharma.com/role/StockbasedCompensationTables 60 false false R61.htm 161 - Disclosure - INCOME TAXES (Details) Sheet http://www.biosantepharma.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.biosantepharma.com/role/IncomeTaxesTables 61 false false R62.htm 162 - Disclosure - INCOME TAXES (Details 1) Sheet http://www.biosantepharma.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://www.biosantepharma.com/role/IncomeTaxesTables 62 false false R63.htm 163 - Disclosure - INCOME TAXES (Details 2) Sheet http://www.biosantepharma.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://www.biosantepharma.com/role/IncomeTaxesTables 63 false false R64.htm 164 - Disclosure - INCOME TAXES (Details Textual) Sheet http://www.biosantepharma.com/role/IncomeTaxesDetailsTextual INCOME TAXES (Details Textual) Details http://www.biosantepharma.com/role/IncomeTaxesTables 64 false false R65.htm 165 - Disclosure - COLLABORATIVE ARRANGEMENTS (Details Textual) Sheet http://www.biosantepharma.com/role/CollaborativeArrangementsDetailsTextual COLLABORATIVE ARRANGEMENTS (Details Textual) Details http://www.biosantepharma.com/role/CollaborativeArrangements 65 false false R66.htm 166 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.biosantepharma.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.biosantepharma.com/role/CommitmentsAndContingenciesTables 66 false false R67.htm 167 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Textual) Sheet http://www.biosantepharma.com/role/CommitmentsAndContingenciesDetailsTextual COMMITMENTS AND CONTINGENCIES (Details Textual) Details http://www.biosantepharma.com/role/CommitmentsAndContingenciesTables 67 false false R68.htm 168 - Disclosure - QUARTERLY FINANCIAL DATA (Details) Sheet http://www.biosantepharma.com/role/QuarterlyFinancialDataDetails QUARTERLY FINANCIAL DATA (Details) Details http://www.biosantepharma.com/role/QuarterlyFinancialDataTables 68 false false R69.htm 169 - Disclosure - QUARTERLY FINANCIAL DATA (Details Textual) Sheet http://www.biosantepharma.com/role/QuarterlyFinancialDataDetailsTextual QUARTERLY FINANCIAL DATA (Details Textual) Details http://www.biosantepharma.com/role/QuarterlyFinancialDataTables 69 false false R70.htm 170 - Disclosure - SUBSEQUENT EVENTS (Details Textual) Sheet http://www.biosantepharma.com/role/SubsequentEventsDetailsTextual SUBSEQUENT EVENTS (Details Textual) Details http://www.biosantepharma.com/role/SubsequentEvents 70 false false All Reports Book All Reports anip-20151231.xml anip-20151231.xsd anip-20151231_cal.xml anip-20151231_def.xml anip-20151231_lab.xml anip-20151231_pre.xml true true ZIP 90 0001144204-16-083848-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-083848-xbrl.zip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

Delaware		58-2301143
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

210 Main Street West
Baudette, Minnesota		56623
(Address of principal executive offices)		(Zip Code)

Title of each class		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		The NASDAQ Global Market

		Page
PART I
Item 1.	Business	2
Item 1A.	Risk Factors	13
Item 1B.	Unresolved Staff Comments	32
Item 2.	Properties	32
Item 3.	Legal Proceedings	33
Item 4.	Mine Safety Disclosures	33

PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	34
Item 6.	Selected Consolidated Financial Data	36
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	37
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	56
Item 8.	Consolidated Financial Statements and Supplementary Data	57
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	93
Item 9A.	Controls and Procedures	93
Item 9B.	Other Information	94

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	95
Item 11.	Executive Compensation	95
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	95
Item 13.	Certain Relationships and Related Transactions, and Director Independence	95
Item 14.	Principal Accountant Fees and Services	95

PART IV
Item 15.	Exhibits and Financial Statement Schedules	96

Signatures		97

Generic Products		Branded Products
Esterified Estrogen with Methyltestosterone		Cortenema
Etodolac		Lithobid
Flecainide		Reglan
Fluvoxamine		Vancocin
Hydrocortisone Enema
Methazolamide
Metoclopramide Syrup
Nimodipine
Opium Tincture
Oxycodone Oral Solution
Propafenone
Vancomycin

	Common Stock Price
	2015				2014
	High		Low		High		Low
First Quarter	$	71.78	$	50.70	$	38.74	$	18.52
Second Quarter	$	72.61	$	47.56	$	37.74	$	19.90
Third Quarter	$	73.54	$	37.20	$	38.17	$	25.17
Fourth Quarter	$	50.07	$	36.15	$	61.43	$	24.24

(in thousands)	December 31,
	2015		2014
Cash and cash equivalents	$	154,684	$	169,037
Accounts receivable, net		21,932		17,297
Inventories, net		13,387		7,518
Prepaid income taxes		1,127		-
Prepaid expenses and other current assets		1,453		1,139
Total current assets	$	192,583	$	194,991

Accounts payable	$	2,066	$	2,654
Accrued expenses		617		567
Accrued royalties		606		702
Accrued compensation and related expenses		1,188		1,348
Accrued income taxes		-		4,253
Accrued Medicaid rebates		4,631		2,264
Returned goods reserve		2,648		1,445
Total current liabilities	$	11,756	$	13,233

(in thousands)	Payments Due by Period
	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Long-term debt obligations ⁽¹⁾	$	143,750	$	-	$	-	$	143,750	$	-
Interest on long-term debt obligations ⁽²⁾		16,891		4,313		8,625		3,953		-
Operating lease obligations		132		55		77		-		-
Upfront purchase price of Corticotropin and Corticotropin-Zinc NDAs ⁽³⁾		75,000		75,000		-		-		-
Purchase obligations		17,989		8,220		8,169		1,600		-
Total	$	253,762	$	87,588	$	16,871	$	149,303	$	-

	December 31, 2015			December 31, 2014

Assets

Current Assets
Cash and cash equivalents	$	154,684		$	169,037
Accounts receivable, net of $13,586 and $8,708 of adjustments for chargebacks and other allowances at December 31, 2015 and 2014, respectively		21,932			17,297
Inventories, net		13,387			7,518
Prepaid income taxes		1,127			-
Prepaid expenses and other current assets		1,453			1,139
Total Current Assets		192,583			194,991

Property and equipment, net		7,131			5,223
Deferred tax asset, net of valuation allowance		17,316			15,439
Intangible assets, net		66,397			42,067
Goodwill		1,838			1,838

Total Assets	$	285,265		$	259,558
Liabilities and Stockholders' Equity

Current Liabilities
Accounts payable	$	2,066		$	2,654
Accrued expenses and other		617			567
Accrued royalties		606			702
Accrued compensation and related expenses		1,188			1,348
Current income taxes payable		-			4,253
Accrued Medicaid rebates		4,631			2,264
Returned goods reserve		2,648			1,445
Total Current Liabilities		11,756			13,233

Long-term Liabilities
Convertible notes, net of discount and deferred financing costs		113,427			106,540
Total Liabilities	$	125,183		$	119,773

Commitments and Contingencies (Note 12)

Stockholders' Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 11,498,228 shares issued and oustanding at December 31, 2015; 11,387,860 shares issued and outstanding at December 31, 2014		1			1
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December 31, 2015 and 2014, respectively		-			-
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December 31, 2015 and 2014, respectively		-			-
Additional paid-in capital		164,431			159,509
Accumulated deficit		(4,350	)		(19,725	)
Total Stockholders' Equity		160,082			139,785

Total Liabilities and Stockholders' Equity	$	285,265		$	259,558

		Common	Common		Class C		Additional		Treasury
		Stock	Stock		Special		Paid-in		Stock			Treasury			Accumulated
		Par Value	Shares		Stock		Capital		Shares			Stock			Deficit			Total

Balance, December 31, 2012	$	-	4,070	$	-	$	1,083		-		$	-		$	(43,798	)	$	(42,715	)
Preferred Stock Dividends		-	-		-		-		-			-			(4,975	)		(4,975	)
Non-cash Compensation Relating to Business Combination		-	-		-		4,418		-			-			-			4,418
Cancellation of Convertible Preferred Stock		-	-		-		53,726		-			-			-			53,726
Shares Issued in Merger		1	5,469		-		29,794		-			-			-			29,795
Stock-based Compensation Expense		-	-		-		36		-			-			-			36
Purchase of Common Stock for Treasury		-	-		-		-		59			(433	)		-			(433	)
Issuance of Common Stock upon Warrant Exercise		-	90		-		809		-			-			-			809
Issuance of Restricted Stock Awards		-	-		-		(365	)	(50	)		365			-			-
Net Income		-	-		-		-		-			-			301			301

Balance, December 31, 2013	$	1	9,629	$	-	$	89,501		9		$	(68	)	$	(48,472	)	$	40,962
Stock-based Compensation Expense		-	-		-		3,423		-			-			-			3,423
Issuance of Common Stock in Equity Offering		-	1,613		-		46,680		-			-			-			46,680
Allocation of proceeds from sale of Convertible Notes to Embedded Conversion Option		-	-		-		20,195		-			-			-			20,195
Cost of Bond-hedge, Net of Proceeds from Sale of Warrant		-	-		-		(2,575	)	-			-			-			(2,575	)
Issuance of Common Stock upon Warrant Exercise		-	83		-		750		-			-			-			750
Issuance of Common Shares upon Stock Option Exercise		-	43		-		819		-			-			-			819
Issuance of Restricted Stock Awards		-	20		-		(68	)	(9	)		68			-			-
Excess Tax Benefit from Stock-based Compensation Awards		-	-		-		784		-			-			-			784
Net Income		-	-		-		-		-			-			28,747			28,747

Balance, December 31, 2014	$	1	11,388	$	-	$	159,509		-		$	-		$	(19,725	)	$	139,785
Stock-based Compensation Expense		-	-		-		3,856		-			-			-			3,856
Changes in Treasury Stock Related to Stock-based Compensation Arrangements		-	-		-		-		7			(113	)		-			(113	)
Issuance of Common Shares upon Stock Option Exercise		-	84		-		706		(5	)		113			-			819
Issuance of Restricted Stock Awards		-	26		-		-		(2	)		-			-			-
Excess Tax Benefit from Stock-based Compensation Awards		-	-		-		360		-			-			-			360
Net Income		-	-		-		-		-			-			15,375			15,375

Balance, December 31, 2015	$	1	11,498	$	-	$	164,431		-		$	-		$	(4,350	)	$	160,082

For the years ended December 31,	2015			2014			2013

Cash Flows From Operating Activities
Net income	$	15,375		$	28,747		$	301
Adjustments to reconcile net loss to net cash and cash equivalents provided by/(used in) operating activities:
Stock-based compensation		3,856			3,423			36
Deferred taxes		(1,877	)		(14,459	)		-
Depreciation and amortization		6,900			3,878			1,110
Loss on disposal of property and equipment		40			-			-
Non-cash interest relating to convertible notes and loan cost amortization		6,831			559			217
Non-cash compensation relating to business combination		-			-			4,418
Changes in operating assets and liabilities, net of those acquired in business combination:
Accounts receivable, net		(4,635	)		(4,784	)		(7,081	)
Inventories, net		(5,869	)		(3,468	)		(708	)
Prepaid expenses and other current assets		(314	)		(558	)		(188	)
Accounts payable		(1,027	)		225			(565	)
Accrued compensation and related expenses		(160	)		575			(2,854	)
Current income taxes, net		(5,380	)		4,233			20
Accrued Medicaid rebates		2,367			2,011			72
Accrued expenses, returned goods reserve and other		1,157			1,651			(67	)
Net Cash and Cash Equivalents Provided by/(Used in) Continuing Operations		17,264			22,033			(5,289	)
Net Cash Used in Discontinued Operation		-			-			(195	)
Net Cash and Cash Equivalents Provided by/(Used in) Operating Activities		17,264			22,033			(5,484	)

Cash Flows From Investing Activities
Cash acquired in business combination		-			-			18,198
Acquisition of product rights and other related assets		(30,500	)		(34,634	)		-
Release of restricted cash		-			-			2,260
Acquisition of property and equipment		(2,183	)		(1,120	)		(191	)
Net Cash and Cash Equivalents (Used in)/Provided by Investing Activities		(32,683	)		(35,754	)		20,267

Cash Flows From Financing Activities
Net proceeds from equity offering		-			46,680			-
Net proceeds from convertible debt offering		-			138,243			-
Purchase of call option overlay, net		-			(15,623	)		-
Repayment of line of credit, net		-			-			(4,065	)
Proceeds from stock option exercises		819			819			-
Proceeds from warrant exercise		-			750			809
Excess tax benefit from share-based compensation awards		360			784			-
Treasury stock purchases		(113	)		-			(433	)
Net Cash and Cash Equivalents Provided by/(Used in) Financing Activities		1,066			171,653			(3,689	)

Change in Cash and Cash Equivalents		(14,353	)		157,932			11,094

Cash and cash equivalents, beginning of period		169,037			11,105			11

Cash and cash equivalents, end of period	$	154,684		$	169,037		$	11,105

Supplemental disclosure for cash flow information:
Cash paid for interest	$	4,205		$	-		$	250
Cash paid for income taxes, net	$	13,255		$	147			-
Supplemental non-cash investing and financing activities:
Property and equipment purchased and included in accounts payable	$	439		$	-		$	-
Issuance of common stock in connection with business combination	$	-		$	-		$	40,034
Cancellation of Series D, Series C, Series B, and Series A preferred stock	$	-		$	-		$	53,726
Acquired non-cash net assets	$	-		$	-		$	11,597
Preferred stock dividends accrued	$	-		$	-		$	4,975

(in thousands, except per share and remaining term data)	Option Shares			Weighted Average Exercise Price		Weighted Average Grant-date Fair Value		Weighted Average Remaining Term (years)		Aggregate Intrinsic Value
Outstanding December 31, 2012		-		$	-				-	$	-
Net BioSante stock options assumed		99			59.59
Granted		21			6.36	$	3.40
Exercised		-			-						-
Forfeited or expired		-			-
Outstanding December 31, 2013		120		$	50.35				2.4	$	81
Granted		120			31.59	$	16.84
Options previously granted, approved by shareholders		325			6.39
Exercised		(43	)		19.45						638
Forfeited		(4	)		6.36
Expired		(60	)		73.96
Outstanding December 31, 2014		458		$	14.44				8.7	$	19,472
Granted		138			62.07	$	30.08
Exercised		(89	)		9.24						3,937
Forfeited		(33	)		11.81
Expired		-			-
Outstanding December 31, 2015		474		$	29.40				8.2	$	10,136
Exercisable at December 31, 2015		101		$	17.97				7.4	$	3,069
Vested or expected to vest at December 31, 2015		464		$	29.06				8.2	$	10,046

(in thousands, except per share and remaining term data)	Shares			Weighted Average Grant Date Fair Value		Weighted Average Remaining Term (years)
Unvested at December 31, 2012		-		$	-
Granted		50			10.20
Vested		-			-
Forfeited		-			-
Unvested at December 31, 2013		50		$	10.20		2.8
Granted		30			29.61
Vested		(17	)		10.20
Forfeited		-			-
Unvested at December 31, 2014		63		$	19.34		2.6
Granted		28			67.26
Vested		(23	)		15.82
Forfeited		(5	)		19.41
Unvested at December 31, 2015		63		$	42.72		2.2

(in thousands)
Year	Minimum Annual Rental Payments
2016	$	55
2017		46
2018		31
2019		-
2020		-
Thereafter		-
Total	$	132

ANI PHARMACEUTICALS, INC.

By:	/s/ Arthur S. Przybyl
	Arthur S. Przybyl
	President and Chief Executive Officer
	(principal executive officer)

By:	/s/ Charlotte C. Arnold
	Charlotte C. Arnold
	Vice President, Finance and
	Chief Financial Officer
	(principal financial officer)

Name	Capacity	Date

/s/ Arthur S. Przybyl	Director, President and	February 23, 2016
Arthur S. Przybyl	Chief Executive Officer

/s/ Robert E. Brown, Jr.	Director and Chairman of the Board of	February 23, 2016
Robert E. Brown, Jr.	Directors

/s/ Fred Holubow	Director	February 23, 2016
Fred Holubow

/s/ Peter A. Lankau	Director	February 23, 2016
Peter A. Lankau

/s/ Tracy L. Marshbanks, Ph.D.	Director	February 23, 2016
Tracy L. Marshbanks, Ph.D.

/s/ Thomas A. Penn	Director	February 23, 2016
Thomas A. Penn

/s/ Daniel Raynor	Director	February 23, 2016
Daniel Raynor

Exhibit No.	Exhibit	Method of Filing

2.1	Amended and Restated Agreement and Plan of Merger, dated as of April 12, 2013, by and among BioSante Pharmaceuticals, Inc., ANI Merger Sub, Inc. and ANIP Acquisition Company (1)	Incorporated by reference to Exhibit 2.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on April 12, 2013 (File No. 001-31812)

2.2	Asset Purchase Agreement, dated as of December 26, 2013, by and between ANI Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. (2)	Incorporated by reference to Exhibit 2.2 to ANI's Annual Report on Form 10-K as filed for the fiscal year ended December 31, 2013 (File No. 001-31812)

3.1	Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of July 17, 2013, Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of June 1, 2012, and Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc.	Incorporated by reference to Exhibit 3.1 to ANI's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013 (File No. 001-31812)

3.2	Amended and Restated Bylaws of BioSante Pharmaceuticals, Inc.	Incorporated by reference to Exhibit 3.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 11, 2010 (File No. 001-31812)

4.1	Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of September 2010	Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on March 5, 2010 (File No. 001-31812)

4.2	Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of June 2010	Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 21, 2010 (File No. 001-31812)

4.3	Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of December 2010	Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on December 29, 2010 (File No. 001-31812)

Name		State of Incorporation
ANIP Acquisition Company		Delaware

Date: February 23, 2016		/s/ Arthur S. Przybyl
		Arthur S. Przybyl
		President and Chief Executive Officer

Dated: February 23, 2016		/s/ Arthur S. Przybyl
		Arthur S. Przybyl
		President and
		Chief Executive Officer
		(principal executive officer)